<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Docetaxel: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Docetaxel: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Docetaxel: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="10751" href="/d/html/10751.html" rel="external">see "Docetaxel: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="13011" href="/d/html/13011.html" rel="external">see "Docetaxel: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708706"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Increased mortality:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Treatment-related mortality associated with docetaxel is increased in patients with abnormal liver function, patients receiving higher doses, and patients with non-small cell lung cancer and a history of prior treatment with platinum-based chemotherapy who receive docetaxel as a single agent at a dose of 100 mg/m<sup>2</sup>.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hepatic function impairment:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Avoid the use of docetaxel in patients with bilirubin &gt; ULN, or in patients with AST and/or ALT &gt;1.5 times the ULN concomitant with alkaline phosphatase &gt;2.5 times the ULN. Patients with elevations of bilirubin or abnormalities of transaminase concurrent with alkaline phosphatase are at increased risk for the development of severe neutropenia, febrile neutropenia, infections, severe thrombocytopenia, severe stomatitis, severe skin toxicity, and toxic death. Patients with isolated elevations of transaminase &gt;1.5 times the ULN also had a higher rate of febrile neutropenia. Measure bilirubin, AST or ALT, and alkaline phosphatase prior to each cycle of docetaxel therapy.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Neutropenia:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Do not administer docetaxel to patients with neutrophil counts &lt;1,500 cells/mm<sup>3</sup>. Monitor blood counts frequently as neutropenia may be severe and result in infection.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Do not administer docetaxel to patients who have a history of severe hypersensitivity reactions to docetaxel or to other drugs formulated with polysorbate 80. Severe hypersensitivity reactions have been reported in patients despite dexamethasone premedication. Hypersensitivity reactions require immediate discontinuation of the docetaxel infusion and administration of appropriate therapy.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Fluid retention:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Severe fluid retention occurred in 6.5% (6/92) of patients despite the use of dexamethasone premedication. It was characterized by 1 or more of the following events: poorly tolerated peripheral edema, generalized edema, pleural effusion requiring urgent drainage, dyspnea at rest, cardiac tamponade, or pronounced abdominal distention (due to ascites).</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F162052"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Taxotere [DSC]</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866645"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Taxotere [DSC]</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F162093"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent, Antimicrotubular;</li>
<li>
                        Antineoplastic Agent, Taxane Derivative</li></ul></div>
<div class="block doa drugH1Div" id="F162057"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Neutrophils should recover to &gt;1,500/mm<sup>3</sup> and platelets should recover to &gt;100,000/mm<sup>3</sup> prior to treatment with subsequent cycles. To reduce the potential risk and severity of tumor lysis syndrome, correct high uric acid serum levels and dehydration prior to docetaxel initiation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Premedication:</i> To reduce the incidence and severity of fluid retention and hypersensitivity reactions, the manufacturer recommends premedication for 3 days beginning 1 day prior to docetaxel administration with oral corticosteroids (eg, dexamethasone 8 mg orally twice daily for 3 days beginning 1 day prior to docetaxel). When prednisone is a backbone component of the antineoplastic regimen in the treatment of prostate cancer, administer dexamethasone 8 mg orally at 12 hours, 3 hours, and 1 hour prior to docetaxel. Data from 2 retrospective reviews describe the use a single dose of dexamethasone 10 or 20 mg IV prior to docetaxel (on the day of docetaxel infusion) to prevent hypersensitivity reactions (Lansinger 2021; Masood 2022).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1efa79b4-3fd5-42a4-94bb-d76b3ea2cc11">Anal carcinoma, squamous cell, advanced</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anal carcinoma, squamous cell, advanced (off-label use): </b>Modified DCF regimen: <b>IV:</b> 40 mg/m<sup>2</sup> every 2 weeks (in combination with cisplatin, fluorouracil, and filgrastim) until disease progression or unacceptable toxicity up to a maximum of 8 cycles (Kim 2018).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="71e76000-039f-40ca-9de6-4a08c97ec284">Bladder cancer, advanced or metastatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bladder cancer, advanced or metastatic (off-label use):</b>
<b>IV:</b> 100 mg/m<sup>2</sup> every 3 weeks (as a single agent) until disease progression or unacceptable toxicity (McCaffrey 1997) <b>or</b> 35 mg/m<sup>2</sup> on days 1 and 8 of a 21-day cycle (in combination with gemcitabine and cisplatin) for at least 6 cycles or until disease progression or unacceptable toxicity (Pectasides 2002).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4abf42df-31da-46e7-a404-09d4066dfddc">Bladder cancer, non–muscle invasive, refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bladder cancer, non–muscle invasive, refractory (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Single-agent docetaxel:</i>
<b>Intravesicular instillation:</b> 75 mg per 100 mL NS; retain for 2 hours once weekly for 6 weeks during induction, followed 3 months later by (if complete response to induction) 75 mg per 100 mL NS once a month for up to 9 maintenance treatments (Barlow 2009; Barlow 2013; McKiernan 2006).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Docetaxel/gemcitabine:</i>
<b>Intravesicular instillation: </b>37.5 mg per 50 mL NS; retain for 1 to 2 hours once weekly (gemcitabine is administered and dwelled for 1 to 1.5 hours, followed by docetaxel) for 6 weeks during induction, followed by (if recurrence free) once-monthly maintenance treatments for up to 24 months (Milbar 2017; Steinberg 2015; Steinberg 2020).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f629398a-17b2-4a1a-8177-10deeef034f4">Breast cancer</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Breast cancer:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Locally advanced or metastatic:</i>
<b>IV:</b> 60 to 100 mg/m<sup>2</sup> every 3 weeks (as a single agent) until disease progression or unacceptable toxicity for at least 6 cycles (Harvey 2006) <b>or</b> 100 mg/m<sup>2</sup> every 3 weeks (as a single agent) for a maximum of 7 or 10 cycles (Chan 1999; Nabholtz 1999).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Operable, node-positive (adjuvant treatment):</i>
<b>IV:</b> TAC regimen: 75 mg/m<sup>2</sup> every 3 weeks for 6 courses (in combination with doxorubicin and cyclophosphamide) (Mackey 2013; Martin 2005).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Adjuvant treatment (off-label dosing):</i>
<b> IV:</b> 75 mg/m<sup>2</sup> every 21 days (in combination with cyclophosphamide) for 4 cycles (Jones 2006; Jones 2009) <b>or</b> 75 mg/m<sup>2</sup> every 21 days (in combination with carboplatin and trastuzumab) for 6 cycles (Slamon 2011) <b>or</b> 75 mg/m<sup>2</sup> every 21 days (in combination with cyclophosphamide and trastuzumab) for 4 cycles (Jones 2013).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Neoadjuvant treatment (off-label dosing):</i>
<b>IV:</b> 75 mg/m<sup>2</sup> (cycle 1; if tolerated, may increase to 100 mg/m<sup>2</sup> in subsequent cycles) every 21 days for a total of 4 cycles (in combination with trastuzumab and pertuzumab) (Gianni 2012) <b>or</b> 75 mg/m<sup>2</sup> every 21 days for 6 cycles (in combination with carboplatin and WBC growth factor support) (Sharma 2017; Sharma 2018) <b>or</b> 75 mg/m<sup>2</sup> every 21 days for 6 cycles (in combination with carboplatin, trastuzumab, and pertuzumab) (Schneeweiss 2013) <b>or </b>75 mg/m<sup>2</sup> initially (if tolerated, may increase to 100 mg/m<sup>2</sup> in subsequent cycles) every 21 days for 3 cycles (following 3 cycles of fluorouracil, epirubicin, and cyclophosphamide and in combination with trastuzumab and pertuzumab) (Schneeweiss 2013).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Metastatic treatment (off-label dosing):</i></p>
<p style="text-indent:-2em;margin-left:6em;">Every-3-week administration: <b>IV:</b> 75 mg/m<sup>2</sup> (cycle 1; may increase to 100 mg/m<sup>2</sup> in subsequent cycles) every 21 days for at least 6 cycles (in combination with trastuzumab and pertuzumab) (Baselga 2012; Swain 2013) <b>or</b> 100 mg/m<sup>2</sup> every 21 days (in combination with trastuzumab) for at least 6 cycles (Marty 2005) <b>or</b> 75 mg/m<sup>2</sup> every 21 days (in combination with capecitabine) until disease progression or unacceptable toxicity (O’Shaughnessy 2002) <b>or</b> 60 mg/m<sup>2</sup>, 75 mg/m<sup>2</sup>, or 100 mg/m<sup>2</sup> every 21 days for at least 6 cycles until disease progression, unacceptable toxicity, or discontinuation (Harvey 2006).</p>
<p style="text-indent:-2em;margin-left:6em;">Weekly administration: <b>IV:</b> 40 mg/m<sup>2 </sup>once a week (as a single agent) for 6 weeks followed by a 2-week rest, repeat until disease progression or unacceptable toxicity (Burstein 2000) <b>or</b> 35 mg/m<sup>2</sup> once weekly for 3 weeks, followed by a 1-week rest, may increase to 40 mg/m<sup>2</sup> once weekly for 3 weeks followed by a 1-week rest with cycle 2 (Rivera 2008) <b>or</b> 35 mg/m<sup>2</sup> once weekly (in combination with trastuzumab) for 3 weeks followed by a 1-week rest; repeat until disease progression or unacceptable toxicity (Esteva 2002).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e50dc227-3f50-48ae-aba5-898bd2fb9c33">Esophageal cancer</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Esophageal cancer (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Sequential chemotherapy and chemoradiation:</i>
<b>IV:</b> Induction: 75 mg/m<sup>2</sup> on days 1 and 22 (in combination with cisplatin) for 2 cycles, followed by chemoradiation: 20 mg/m<sup>2</sup> weekly for 5 weeks (in combination with cisplatin and radiation) (Ruhstaller 2009).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Definitive chemoradiation:</i>
<b>IV:</b> 60 mg/m<sup>2</sup> on days 1 and 22 (in combination with cisplatin and radiation) for 1 cycle (Li 2010).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Locally advanced, resectable </i>
<i>gastroesophageal junction adenocarcinoma</i>: <b>IV: </b>50 mg/m<sup>2</sup> on day 1 every 2 weeks (in combination with fluorouracil, leucovorin, and oxaliplatin; FLOT regimen) for 4 preoperative and 4 postoperative cycles (Al-Batran 2019).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Locally advanced or metastatic disease:</i>
<b>IV:</b> 75 mg/m<sup>2</sup> on day 1 every 3 weeks (in combination with cisplatin and fluorouracil) (Ajani 2007; Van Cutsem 2006) <b>or</b> 40 mg/m<sup>2</sup> on day 1 every 2 weeks (in combination with fluorouracil, leucovorin, and cisplatin) until disease progression or unacceptable toxicity (Shah 2015) <b>or</b> 50 mg/m<sup>2</sup> on day 1 every 2 weeks (in combination with fluorouracil, leucovorin, and oxaliplatin) until disease progression or unacceptable toxicity up to a maximum of 8 cycles (Al-Batran 2008) <b>or</b> 35 mg/m<sup>2</sup> on days 1, 8, 15, 29, 36, 43, 50, and 57 (in combination with cisplatin, fluorouracil, and radiotherapy; neoadjuvant setting) (Pasini 2013).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="281ac050-6cae-487a-9b8a-81245c77082d">Ewing sarcoma, recurrent or refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ewing sarcoma, recurrent or refractory (off-label use; based on limited data):</b>
<b>IV: </b>75 to 100 mg/m<sup>2</sup> on day 8 of a 21-day cycle (in combination with gemcitabine) (Fox 2012; Navid 2008).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="25c1a9d0-4f24-4367-997a-ebc46b20eb68">Gastric adenocarcinoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gastric adenocarcinoma</b>
<b>:</b>
<b>IV:</b> 75 mg/m<sup>2</sup> every 3 weeks (in combination with cisplatin and fluorouracil) until disease progression or unacceptable toxicity (Van Cutsem 2006).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Sequential chemotherapy and chemoradiation (off-label dosing):</i> Induction: <b>IV:</b> 75 mg/m<sup>2</sup> on days 1 and 22 (in combination with cisplatin) for 2 cycles, followed by chemoradiation: 20 mg/m<sup>2</sup> weekly for 5 weeks (in combination with cisplatin and radiation) (Ruhstaller 2009).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Locally advanced resectable disease (off-label dosing): </i>
<b>IV: </b>50 mg/m<sup>2</sup> on day 1 every 2 weeks (in combination with fluorouracil, leucovorin, and oxaliplatin; FLOT regimen) for 4 preoperative and 4 postoperative cycles (Al-Batran 2019).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Locally advanced or metastatic disease (off-label dosing):</i>
<b>IV: </b>40 mg/m<sup>2</sup> on day 1 every 2 weeks (in combination with fluorouracil, leucovorin, and cisplatin) until disease progression or unacceptable toxicity (Shah 2015) <b>or </b>50 mg/m<sup>2</sup> on day 1 every 2 weeks (in combination with fluorouracil, leucovorin, and oxaliplatin) until disease progression or unacceptable toxicity up to a maximum of 8 cycles (Al-Batran 2008).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="01cd0f58-ce35-4245-b8e0-406d23a85003">Head and neck cancer</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Head and neck cancer:</b>
<b>IV:</b> 75 mg/m<sup>2</sup> every 3 weeks (in combination with cisplatin and fluorouracil) for 3 or 4 cycles, followed by radiation therapy (Posner 2007; Vermorken 2007).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Nasopharyngeal carcinoma, locally advanced:</i>
<b>IV:</b> 60 mg/m<sup>2</sup> every 3 weeks (in combination with cisplatin and fluorouracil) for 3 induction cycles, followed by concurrent chemoradiotherapy (Sun 2016) <b>or</b> 75 mg/m<sup>2</sup> every 3 weeks (in combination with cisplatin) for 2 cycles, followed by chemoradiotherapy (Hui 2009).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c818fdd2-0859-4362-9aae-976c7de99cda">Non–small cell lung cancer</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Non–small cell lung cancer: IV:</b> 75 mg/m<sup>2</sup> every 3 weeks (as a single agent) for at least 6 cycles or until disease progression or unacceptable toxicity (Fossella 2000; Shepherd 2000) <b>or</b> (in combination with cisplatin) for at least 6 cycles or until disease progression or unacceptable toxicity (Fossella 2003).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Off-label combinations: </i>
<b>IV:</b> 75 mg/m<sup>2</sup> every 3 weeks (in combination with carboplatin) for at least 6 cycles or until disease progression or unacceptable toxicity (Fossella 2003) <b>or </b>85 mg/m<sup>2</sup> on day 8 of a 3-week treatment cycle (in combination with gemcitabine) for 8 cycles or until disease progression or unacceptable toxicity (Pujol 2005) <b>or</b> 75 mg/m<sup>2</sup> every 3 weeks (in combination with ramucirumab) until disease progression or unacceptable toxicity (Garon 2014).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a3b2a31a-4491-4171-b3cf-0a4e46585277">Osteosarcoma, recurrent or refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Osteosarcoma, recurrent or refractory (off-label use):</b>
<b>IV: </b>75 to 100 mg/m<sup>2</sup> on day 8 of a 21-day cycle (in combination with gemcitabine) until disease progression or unacceptable toxicity (Fox 2012; Navid 2008; Palmerini 2016).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7322d635-ec03-41b2-b458-e6daed980825">Ovarian cancer</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ovarian cancer (off-label use):</b>
<b>IV:</b> 60 mg/m<sup>2</sup> every 3 weeks (in combination with carboplatin) for up to 6 cycles (Markman 2001) <b>or</b> 75 mg/m<sup>2</sup> every 3 weeks (in combination with carboplatin) for 6 cycles (Vasey 2004) <b>or</b> 35 mg/m<sup>2</sup> (maximum dose: 70 mg) weekly for 3 weeks followed by a 1-week rest (in combination with carboplatin) (Kushner 2007).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="34a0d01f-7598-4295-91fc-098cdd1ce6dd">Prostate cancer, metastatic, castration resistant</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Prostate cancer, metastatic, castration resistant:</b>
<b>IV:</b> 75 mg/m<sup>2</sup> every 3 weeks (in combination with prednisone) (Tannock 2004).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Docetaxel/carboplatin (off-label combination):</i>
<b>IV: </b>75 mg/m<sup>2</sup> every 3 weeks (in combination with carboplatin) for at least 4 cycles or until disease progression or unacceptable toxicity (Aparicio 2013).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="470fdbf3-e774-4f25-8ef5-950eca6f9150">Prostate cancer, metastatic, hormone sensitive</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Prostate cancer</b>
<b>, metastatic</b>
<b>, hormone sensitive (off-label use): IV: </b>75 mg/m<sup>2 </sup>on day 1 every 3 weeks (in combination with androgen-deprivation therapy and prednisolone) for 6 cycles (James 2016) <b>or</b> 75 mg/m<sup>2</sup> on day 1 every 3 weeks (in combination with androgen-deprivation therapy; daily prednisone not required) for 6 cycles (Sweeney 2015) <b>or </b>75 mg/m<sup>2 </sup>on day 1 every 3 weeks (in combination with darolutamide and androgen-deprivation therapy) for 6 cycles; darolutamide was continued after the 6 docetaxel cycles (Smith 2022)<b> or </b>75 mg/m<sup>2 </sup>(maximum dose: 150 mg) on day 1 every 3 weeks (in combination with abiraterone, prednisone, and androgen-deprivation therapy) for 6 cycles; abiraterone and prednisone were continued after the 6 docetaxel cycles (Fizazi 2022).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b23c068c-3295-4492-8a43-96f50e8bde7b">Small cell lung cancer, relapsed</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Small cell lung cancer, relapsed (off-label use):</b>
<b>IV:</b> 100 mg/m<sup>2</sup> every 3 weeks (Smyth 1994).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fd3af387-555a-4a6b-ba66-b23086fe5ba6">Soft tissue sarcoma, recurrent or progressive</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Soft tissue sarcoma, recurrent or progressive (off-label use): IV:</b> 100 mg/m<sup>2</sup> on day 8 of a 3-week treatment cycle (in combination with gemcitabine and filgrastim or pegfilgrastim) (Leu 2004; Maki 2007).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="dcf9a493-2b6b-462b-ae42-474e90075db4">Thyroid carcinoma, anaplastic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Thyroid carcinoma, anaplastic (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Adjuvant or radiosensitizing therapy:</i>
<b> IV: </b>60 mg/m<sup>2</sup> on day 1 every 3 to 4 weeks (in combination with doxorubicin and pegfilgrastim) for ~4 cycles (ATA [Smallridge 2012]; Foote 2011) <b>or</b> 20 mg/m<sup>2</sup> once weekly (in combination with doxorubicin) (ATA [Smallridge 2012]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Advanced or metastatic disease:</i>
<b> IV: </b>60 mg/m<sup>2</sup> on day 1 every 3 to 4 weeks (in combination with doxorubicin and pegfilgrastim) <b>or</b> 20 mg/m<sup>2</sup> once weekly (in combination with doxorubicin) (ATA [Smallridge 2012]).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9423dd95-32f0-4da8-9713-ec32b6f85b8b">Unknown primary, adenocarcinoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Unknown primary, adenocarcinoma (off-label use):</b>
<b>IV:</b> 65 mg/m<sup>2</sup> every 3 weeks (in combination with carboplatin) (Greco 2000) <b>or</b> 75 mg/m<sup>2</sup> on day 8 of a 3-week treatment cycle (in combination with gemcitabine) for up to 6 cycles (Pouessel 2004) <b>or</b> 60 mg/m<sup>2</sup> on day 1 of a 3-week treatment cycle (in combination with cisplatin) (Mukai 2010).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="afd384df-555e-4696-b003-d562e1b00bff">Uterine leiomyosarcoma, advanced or high-grade</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Uterine leiomyosarcoma, advanced or high-grade (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Unresectable leiomyosarcoma:</i>
<b> IV: </b>100 mg/m<sup>2</sup> (75 mg/m<sup>2</sup> if received prior radiation therapy) on day 8 of a 3-week treatment cycle (in combination with gemcitabine and filgrastim) for 6 cycles (Hensley 2002).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>High-grade leiomyosarcoma, previously untreated:</i>
<b> IV: </b>75 mg/m<sup>2</sup> on day 8 of a 3-week treatment cycle (in combination with gemcitabine and filgrastim or pegfilgrastim) for 4 cycles (Hensley 2009) <b>or </b>75 mg/m<sup>2</sup> on day 8 of a 3-week treatment cycle (in combination with gemcitabine) for up to 6 cycles in the absence of disease progression or unacceptable toxicity (Seddon 2017).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Metastatic leiomyosarcoma:</i>
<b> IV: </b>75 mg/m<sup>2</sup> (60 mg/m<sup>2</sup> if received prior radiation therapy) on day 8 of a 3-week treatment cycle (in combination with gemcitabine and filgrastim or pegfilgrastim) until disease progression or unacceptable toxicity (Hensley 2015).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990805"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> No dosage adjustment necessary for any degree of kidney dysfunction (~6% eliminated in urine) (Dimopoulos 1998; Li 2007; expert opinion).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Not significantly dialyzed (Hochegger 2007; Janus 2010; Mencoboni 2006; Yang 2015): No supplemental dose or dosage adjustment necessary (Janus 2010; Krens 2019; expert opinion).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Unlikely to be significantly dialyzed (highly protein bound): No dosage adjustment necessary (Kaneda 2012; expert opinion).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> No dosage adjustment necessary (expert opinion).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> No dosage adjustment necessary (expert opinion).</p></div>
<div class="block doha drugH1Div" id="F50988004"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> The alcohol content of the docetaxel formulation should be taken into account when administering to patients with hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">Total bilirubin &gt; ULN or AST and/or ALT &gt;1.5 times ULN concomitant with alkaline phosphatase &gt;2.5 times ULN: Avoid docetaxel use.</p>
<p style="text-indent:-2em;margin-left:2em;">Isolated transaminase elevations &gt;1.5 times ULN: Consider docetaxel dose modification.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic impairment dosing adjustment specific for gastric or head and neck cancer:</p>
<p style="text-indent:-2em;margin-left:4em;">AST/ALT &gt;2.5 to ≤5 times ULN and alkaline phosphatase ≤2.5 times ULN: Administer 80% of dose.</p>
<p style="text-indent:-2em;margin-left:4em;">AST/ALT &gt;1.5 to ≤5 times ULN and alkaline phosphatase &gt;2.5 to ≤5 times ULN: Administer 80% of dose.</p>
<p style="text-indent:-2em;margin-left:4em;">AST/ALT &gt;5 times ULN and /or alkaline phosphatase &gt;5 times ULN: Discontinue docetaxel.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>The following adjustments have also been used (Floyd 2006):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Transaminases 1.6 to 6 times ULN: Administer 75% of dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Transaminases &gt;6 times ULN: Use clinical judgment.</p></div>
<div class="block doo drugH1Div" id="F20341640"><span class="drugH1">Dosing: Obesity: Adult</span>
<p style="text-indent:0em;display:inline">
<i>American Society of Clinical Oncology guidelines for appropriate systemic therapy dosing in adults with cancer with a BMI ≥30 kg/m<sup>2</sup>:</i> Utilize patient's actual body weight for calculation of BSA- or weight-based dosing; manage regimen-related toxicities in the same manner as for patients with a BMI &lt;30 kg/m<sup>2</sup>; if a dose reduction is utilized due to toxicity, may consider resumption of full, weight-based dosing (or previously tolerated dose level) with subsequent cycles only if dose escalations are allowed in the prescribing information, if contributing underlying factors (eg, hepatic or kidney impairment) are sufficiently resolved, AND if performance status has markedly improved or is considered adequate (ASCO [Griggs 2021]).</p></div>
<div class="block dot drugH1Div" id="F162094"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Neutrophils should recover to &gt;1,500/mm<sup>3</sup> and platelets should recover to &gt;100,000/mm<sup>3</sup> prior to treatment with subsequent cycles. Hematologic toxicity includes febrile neutropenia, neutrophils &lt;500/mm<sup>3</sup> for &gt;1 week, severe or cumulative cutaneous reactions; in non-small cell lung cancer, this may also include platelet nadir &lt;25,000/mm<sup>3</sup> and other grade 3/4 nonhematologic toxicities.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dermatologic toxicity:</b> Consider permanent docetaxel discontinuation in patients who develop severe cutaneous adverse reactions.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Hypersensitivity:</b> Immediately discontinue docetaxel for severe hypersensitivity reaction (and administer appropriate medical management). Do not rechallenge if severe hypersensitivity occurred.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Neurosensory symptoms (eg, </b>
<b>paresthesia, dysesthesia, pain):</b> Adjust docetaxel dose for severe neurosensory symptoms; discontinue docetaxel for persistent symptoms.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Ocular disorders:</b> Discontinue docetaxel if cystoid macular edema is diagnosed (consider alternate non-taxane therapies). A prompt comprehensive ophthalmic exam is recommended if vision impairment occurs.</p>
<p style="text-indent:-2em;margin-left:2em;">Also refer to specific reference/protocol for dosage adjustments for off-label uses, doses, or combinations.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Breast cancer (single agent):</b> Patients dosed initially at 100 mg/m<sup>2</sup>; reduce dose to 75 mg/m<sup>2</sup>; <b>Note:</b> If the patient continues to experience these adverse reactions, the dosage should be reduced to 55 mg/m<sup>2</sup> or therapy should be discontinued; discontinue for peripheral neuropathy ≥ grade 3. Patients initiated at 60 mg/m<sup>2</sup> who do not develop toxicity may tolerate higher doses.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Breast cancer, adjuvant treatment (combination chemotherapy):</b> TAC regimen should be administered when neutrophils are ≥1,500/mm<sup>3</sup>. Patients experiencing febrile neutropenia should receive G-CSF in all subsequent cycles. Patients with persistent febrile neutropenia (while on G-CSF), patients experiencing severe/cumulative cutaneous reactions, moderate neurosensory effects (signs/symptoms) or grade 3 or 4 stomatitis should receive a reduced dose (60 mg/m<sup>2</sup>) of docetaxel. Discontinue therapy with persistent toxicities after dosage reduction.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Non-small cell lung cancer:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Monotherapy: Patients dosed initially at 75 mg/m<sup>2</sup> should have dose held until toxicity is resolved, then resume at 55 mg/m<sup>2</sup>; discontinue for peripheral neuropathy ≥ grade 3.</p>
<p style="text-indent:-2em;margin-left:4em;">Combination therapy (with cisplatin): Patients dosed initially at 75 mg/m<sup>2</sup> should have the docetaxel dosage reduced to 65 mg/m<sup>2</sup> in subsequent cycles; if further adjustment is required, dosage may be reduced to 50 mg/m<sup>2</sup>.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Prostate cancer:</b> Reduce dose to 60 mg/m<sup>2</sup>; discontinue therapy if toxicities persist at lower dose.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Gastric cancer, head and neck cancer:</b>
<b>Note:</b> Cisplatin may also require dose reductions/therapy delays for peripheral neuropathy, ototoxicity, and/or nephrotoxicity. Patients experiencing febrile neutropenia, documented infection with neutropenia or neutropenia &gt;7 days should receive G-CSF in all subsequent cycles. For neutropenic complications despite G-CSF use, reduce dose to 60 mg/m<sup>2</sup>. Dosing with neutropenic complications in subsequent cycles should be further reduced (following neutrophil recovery to ≥1,500/mm<sup>3</sup>) to 45 mg/m<sup>2</sup>. Patients who experience grade 4 thrombocytopenia should receive a dose reduction from 75 mg/m<sup>2</sup> to 60 mg/m<sup>2 </sup>(following platelet recovery to &gt;100,000/mm<sup>3</sup>). Discontinue therapy for persistent toxicities.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Gastrointestinal toxicity for docetaxel in combination with cisplatin and fluorouracil for treatment of gastric cancer or head and neck cancer:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Diarrhea, grade 3:</p>
<p style="text-indent:-2em;margin-left:8em;">First episode: Reduce fluorouracil dose by 20%.</p>
<p style="text-indent:-2em;margin-left:8em;">Second episode: Reduce docetaxel dose by 20%.</p>
<p style="text-indent:-2em;margin-left:6em;">Diarrhea, grade 4:</p>
<p style="text-indent:-2em;margin-left:8em;">First episode: Reduce fluorouracil and docetaxel doses by 20%.</p>
<p style="text-indent:-2em;margin-left:8em;">Second episode: Discontinue treatment.</p>
<p style="text-indent:-2em;margin-left:6em;">Stomatitis, grade 3:</p>
<p style="text-indent:-2em;margin-left:8em;">First episode: Reduce fluorouracil dose by 20%.</p>
<p style="text-indent:-2em;margin-left:8em;">Second episode: Discontinue fluorouracil for all subsequent cycles.</p>
<p style="text-indent:-2em;margin-left:8em;">Third episode: Reduce docetaxel dose by 20%.</p>
<p style="text-indent:-2em;margin-left:6em;">Stomatitis, grade 4:</p>
<p style="text-indent:-2em;margin-left:8em;">First episode: Discontinue fluorouracil for all subsequent cycles.</p>
<p style="text-indent:-2em;margin-left:8em;">Second episode: Reduce docetaxel dose by 20%.</p></div>
<div class="block doe drugH1Div" id="F162058"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F16148913"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="13011" href="/d/html/13011.html" rel="external">see "Docetaxel: Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Dose, frequency, number of doses, and start date may vary by protocol and treatment phase. Refer to individual protocols: Premedicate with corticosteroids, beginning the day before docetaxel administration (administer corticosteroids for 1 to 3 days), to reduce the severity of hypersensitivity reactions and pulmonary/peripheral edema. For adults, the manufacturer recommends dexamethasone 16 mg (8 mg twice daily) orally for 3 days. In one pediatric clinical trial, dexamethasone 3 mg/m<sup>2</sup> orally or IV every 6 hours for 2 doses, starting 12 hours before docetaxel administration has been described (Zwerdling 2006). Docetaxel is associated with a low emetic potential (POGO [Dupuis 2011]); an antiemetic may be recommended to prevent nausea and vomiting (POGO [Dupuis 2013]).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="36f1796d-1158-42df-a2fa-c50540e1250b">Sarcomas, Ewing Sarcoma; osteosarcoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Sarcomas,</b>
<b>Ewing Sarcoma; osteosarcoma (recurrent or progressive):</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mora 2009</i>: G + D regimen: Children and Adolescents: IV: 100 mg/m<sup>2</sup> over 2 to 4 hours on Day 8 of a 21-day cycle in combination with gemcitabine.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Rapkin 2012</i>: GEMDOX regimen:</p>
<p style="text-indent:-2em;margin-left:6em;">Infants: IV: 2.5 mg/kg over 1 hour on Day 8 of a 21-day cycle in combination with gemcitabine.</p>
<p style="text-indent:-2em;margin-left:6em;">Children and Adolescents: IV: 75 mg/m<sup>2</sup> over 1 hour on Day 8 of a 21-day cycle in combination with gemcitabine.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ce17d3e0-5a62-4c43-92d4-7e6e951d1d27">Hepatoblastoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatoblastoma (refractory or relapsed): </b>Limited data available, case-series reports (George 2012): Infants and Children:</p>
<p style="text-indent:-2em;margin-left:4em;">Patient weight &lt;10 kg: IV: 3.3 mg/kg as a 1-hour infusion every 21 days.</p>
<p style="text-indent:-2em;margin-left:4em;">Patient weight &gt;10 kg: IV: 100 mg/m<sup>2</sup> given as a 1-hour infusion every 21 days.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosing adjustment for toxicity:</b> The presented dosing adjustments are based on experience in adult patients; specific recommendations for pediatric patients are limited. Refer to specific protocol for management in pediatric patients if available.</p>
<p style="text-indent:-2em;margin-left:4em;">Adult: <b>Note:</b> Toxicity includes febrile neutropenia, neutrophils &lt;500/mm<sup>3</sup> for &gt;1 week, severe or cumulative cutaneous reactions; in non-small cell lung cancer, this may also include platelets &lt;25,000/mm<sup>3</sup> and other grade 3/4 nonhematologic toxicities.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Breast cancer (single agent):</b> Patients dosed initially at 100 mg/m<sup>2 </sup>(adult); reduce dose to 75 mg/m<sup>2</sup> (adult); <b>Note:</b> If the patient continues to experience these adverse reactions, the dosage should be reduced to 55 mg/m<sup>2</sup> (adult) or therapy should be discontinued; discontinue for peripheral neuropathy ≥ grade 3. Patients initiated at 60 mg/m<sup>2 </sup>(adult) who do not develop toxicity may tolerate higher doses.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Breast cancer, adjuvant treatment (combination chemotherapy):</b> TAC regimen should be administered when neutrophils are ≥1,500/mm<sup>3</sup>. Patients experiencing febrile neutropenia should receive G-CSF in all subsequent cycles. Patients with persistent febrile neutropenia (while on G-CSF), patients experiencing severe/cumulative cutaneous reactions, moderate neurosensory effects (signs/symptoms) or grade 3 or 4 stomatitis should receive a reduced dose (60 mg/m<sup>2</sup> in adults) of docetaxel. Discontinue therapy with persistent toxicities after dosage reduction.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Non-small cell lung cancer:</b></p>
<p style="text-indent:-2em;margin-left:8em;">Monotherapy: Patients dosed initially at 75 mg/m<sup>2 </sup>(adult) should have dose held until toxicity is resolved, then resume at 55 mg/m<sup>2 </sup>(adult); discontinue for peripheral neuropathy ≥ grade 3.</p>
<p style="text-indent:-2em;margin-left:8em;">Combination therapy (with cisplatin): Patients dosed initially at 75 mg/m<sup>2 </sup>(adult) should have the docetaxel dosage reduced to 65 mg/m<sup>2</sup> (adult) in subsequent cycles; if further adjustment is required, dosage may be reduced to 50 mg/m<sup>2 </sup>(adult).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Prostate cancer:</b> Reduce dose to 60 mg/m<sup>2</sup> (adult); discontinue therapy if toxicities persist at lower dose.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Gastric cancer, head and neck cancer:</b>
<b>Note:</b> Cisplatin may require dose reductions/therapy delays for peripheral neuropathy, ototoxicity, and/or nephrotoxicity. Patients experiencing febrile neutropenia, documented infection with neutropenia or neutropenia &gt;7 days should receive G-CSF in all subsequent cycles. For neutropenic complications despite G-CSF use, further reduce dose to 60 mg/m<sup>2 </sup>(adult). Dosing with neutropenic complications in subsequent cycles should be further reduced to 45 mg/m<sup>2 </sup>(adult). Patients who experience grade 4 thrombocytopenia should receive a dose reduction from 75 mg/m<sup>2</sup> to 60 mg/m<sup>2 </sup> (adult dosing). Discontinue therapy for persistent toxicities.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Gastrointestinal toxicity for docetaxel in combination with cisplatin and fluorouracil for treatment of gastric cancer or head and neck cancer:</i></p>
<p style="text-indent:-2em;margin-left:10em;">Diarrhea, grade 3:</p>
<p style="text-indent:-2em;margin-left:12em;">First episode: Reduce fluorouracil dose by 20%.</p>
<p style="text-indent:-2em;margin-left:12em;">Second episode: Reduce docetaxel dose by 20%.</p>
<p style="text-indent:-2em;margin-left:10em;">Diarrhea, grade 4:</p>
<p style="text-indent:-2em;margin-left:12em;">First episode: Reduce fluorouracil and docetaxel doses by 20%.</p>
<p style="text-indent:-2em;margin-left:12em;">Second episode: Discontinue treatment.</p>
<p style="text-indent:-2em;margin-left:10em;">Stomatitis, grade 3:</p>
<p style="text-indent:-2em;margin-left:12em;">First episode: Reduce fluorouracil dose by 20%.</p>
<p style="text-indent:-2em;margin-left:12em;">Second episode: Discontinue fluorouracil for all subsequent cycles.</p>
<p style="text-indent:-2em;margin-left:12em;">Third episode: Reduce docetaxel dose by 20%.</p>
<p style="text-indent:-2em;margin-left:10em;">Stomatitis, grade 4:</p>
<p style="text-indent:-2em;margin-left:12em;">First episode: Discontinue fluorouracil for all subsequent cycles.</p>
<p style="text-indent:-2em;margin-left:12em;">Second episode: Reduce docetaxel dose by 20%.</p></div>
<div class="block dorp drugH1Div" id="F51117849"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no pediatric specific recommendations available; refer to protocols; based on experience in adult patients, renal excretion is minimal; therefore, the need for dosage adjustments for renal dysfunction is unlikely (Janus 2010; Li 2007). Not removed by hemodialysis; may be administered before or after hemodialysis (Janus 2010).</p></div>
<div class="block dohp drugH1Div" id="F51117850"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no pediatric specific recommendations available; refer to protocols; based on experience in adult patients, dosage adjustment suggested based on elevations of liver enzymes and/or total bilirubin levels.</p></div>
<div class="block adr drugH1Div" id="F162021"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Percentages reported for docetaxel monotherapy; frequency may vary depending on diagnosis, dose, liver function, prior treatment, and premedication.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia (56% to 76%, can be permanent), dermatological reaction (20% to 48%; severe dermatological reaction: 5%), nail disease (11% to 41%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Fluid retention (26% to 60%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (23% to 43%; severe diarrhea: ≤6%), nausea (34% to 42%; severe nausea: ≤5%), stomatitis (19% to 53%; grades 3/4: 2%), vomiting (22% to 23%; severe vomiting: ≤5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (65% to 97%; grades 3/4: 8% to 9%), febrile neutropenia (5% to 14%), leukopenia (84% to 99%; grades 3/4: 49%; grade 4: 32% to 44%), neutropenia (84% to 99%; grades 3/4: 65%; grade 4: 75% to 86%; nadir [median]: 7 days, duration [severe neutropenia]: 7 days), thrombocytopenia (7% to 14%; grades 3/4: 3%; grade 4: 1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase (≤19%), increased aspartate aminotransferase (≤19%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (6% to 21%, including back pain, chest tightness, chills, drug fever, dyspnea, flushing, skin rash; severe hypersensitivity reaction: 3% to 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (1% to 34%; severe infection: 2% to 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Central nervous system toxicity (20% to 58%; including dysesthesia: ≤6%, paresthesia: ≤6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Asthenia (53% to 66%; severe weakness: 13% to 18%), myalgia (3% to 23%; severe myalgia: 2%), neuromuscular reaction (16%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pulmonary disease (41%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (31% to 35%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypotension (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dysgeusia (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alkaline phosphatase (7%), increased serum bilirubin (9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Infusion site reaction (4%; including erythema at injection site, exfoliation of skin, inflammation at injection site, injection site extravasation, local dryness of skin, skin discoloration at injection site, swelling at injection site [vein])</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Peripheral motor neuropathy (4%; severe; mainly distal extremity weakness)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular and skeletal: Arthralgia (3% to 9%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Dermatologic: Onycholysis</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Decreased left ventricular ejection fraction, localized phlebitis</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Localized erythema of the extremities, nail depigmentation, nail hyperpigmentation</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Fatigue</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction, atrial fibrillation, atrial flutter, cardiac arrhythmia, cardiac failure, chest pain, deep vein thrombosis, ECG abnormality, hypertension, pulmonary embolism, sinus tachycardia, syncope, tachycardia, thrombophlebitis, unstable angina pectoris</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acute generalized exanthematous pustulosis, cutaneous lupus erythematosus, dermatological reaction (injection site recall at previous site of extravasation), erythema multiforme, palmar-plantar erythrodysesthesia, skin changes (scleroderma-like), Stevens-Johnson syndrome, toxic epidermal necrolysis</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Electrolyte disorder, hypocalcemia, hypokalemia, hypomagnesemia, hyponatremia</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain, anorexia, colitis, constipation, duodenal ulcer, enterocolitis, esophagitis, gastrointestinal hemorrhage, gastrointestinal perforation, intestinal obstruction, ischemic colitis, neutropenic enterocolitis</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Acute myelocytic leukemia, bleeding tendency disorder, disseminated intravascular coagulation, lymphedema (peripheral), myelodysplastic syndrome, non-Hodgkin's lymphoma, tumor lysis syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Acute hepatic failure (Morgan 2011), hepatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylactic shock, anaphylaxis</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Sepsis</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Confusion, loss of consciousness (transient), pain, seizure</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Myositis</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Conjunctivitis, cystoid macular edema, disease of the lacrimal apparatus (duct obstruction), epiphora (more common with weekly administration [Kintzel 2006]), lacrimation, visual disturbance (transient)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Auditory disturbance, hearing loss, ototoxicity</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Renal failure syndrome, renal insufficiency, renal neoplasm</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Acute respiratory distress, interstitial pulmonary disease, pneumonia (interstitial), pneumonitis, pulmonary edema, pulmonary fibrosis, respiratory failure</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Multi-organ failure, radiation recall phenomenon</p></div>
<div class="block coi drugH1Div" id="F162034"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">History of severe hypersensitivity to docetaxel or any component of the formulation; severe hypersensitivity to other medications containing polysorbate 80; neutrophil count &lt;1,500/mm<sup>3</sup>.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Severe hepatic impairment; pregnancy; breastfeeding.</p></div>
<div class="block war drugH1Div" id="F162018"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bone marrow suppression: Neutropenia may be severe and may result in infection; the dose-limiting toxicity is neutropenia. Patients with increased LFTs experienced more episodes of neutropenia with a greater number of severe infections.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cutaneous reactions: Cutaneous reactions, including erythema (with edema) and desquamation, have been reported. Severe cutaneous adverse reactions such as Stevens-Johnson syndrome, toxic epidermal necrolysis, and acute generalized exanthematous pustulosis have been reported and may be associated with docetaxel.</p>
<p style="text-indent:-2em;margin-left:4em;">• Extravasation: Docetaxel is an irritant with vesicant-like properties; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Fluid retention: Severe fluid retention, characterized by pleural effusion (requiring immediate drainage), ascites with pronounced abdominal distention, peripheral edema (poorly tolerated), dyspnea at rest, cardiac tamponade, and/or generalized edema, has been reported (despite the use of premedication with dexamethasone). Fluid retention may begin as lower extremity peripheral edema and become generalized with a median weight gain of 2 kg. In 92 patients with breast cancer who received corticosteroid premedication, moderate and severe fluid retention occurred in ~27% and ~7%, respectively; the median cumulative dose to onset of moderate or severe fluid retention was 819 mg/m<sup>2</sup>; fluid retention resolves in a median of 16 weeks (range: up to 42 weeks) after discontinuation. Patients should be premedicated with a corticosteroid (starting 1 day prior to administration) to reduce the incidence and severity of fluid retention. Closely monitor patients with existing effusions.</p>
<p style="text-indent:-2em;margin-left:4em;">• GI toxicity: Enterocolitis and neutropenic colitis (typhlitis) have occurred with docetaxel (either as a single agent or in combination with other chemotherapy) and despite administration of filgrastim; may occur at any time and could be fatal on the first day of symptom onset. Use with caution in patients with neutropenia, particularly those at increased risk for developing GI complications. Patients should report new-onset or worsening symptoms of GI toxicity.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Severe hypersensitivity reactions have been reported despite dexamethasone premedication. Severe hypersensitivity reactions have been characterized by generalized rash/erythema, hypotension, bronchospasm, and/or fatal anaphylaxis. Patients with a history of hypersensitivity reaction to paclitaxel may develop hypersensitivity to docetaxel; may be severe or fatal (including anaphylaxis); monitor patients with paclitaxel hypersensitivity closely during initiation of docetaxel therapy. Minor reactions including flushing or localized skin reactions may also occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Neurosensory symptoms: Severe neurosensory symptoms (paresthesia, dysesthesia, pain) have been observed; reversal of symptoms may be delayed after discontinuation. Severe peripheral motor neuropathy manifesting as distal extremity weakness has been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ocular adverse effects: Cystoid macular edema (CME) has been reported; if vision impairment occurs, a prompt comprehensive ophthalmic exam is recommended. In a study of patients receiving docetaxel for the adjuvant treatment of breast cancer, a majority of patients experienced tearing, which occurred in patients with and without lacrimal duct obstruction at baseline. Onset was generally after cycle 1, but subsided in most patients within 4 months after therapy completion (Chan 2013).</p>
<p style="text-indent:-2em;margin-left:4em;">• Secondary malignancies: Second primary malignancies, including acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), non-Hodgkin lymphoma, and renal cancer have occurred in patients several months or years after receiving docetaxel-containing regimens. Treatment-related AML or MDS has occurred in patients receiving docetaxel in combination with anthracyclines and/or cyclophosphamide (with or without fluorouracil), including patients who received docetaxel-containing regimens as adjuvant therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Treatment-related mortality: Treatment-related mortality associated with docetaxel is increased in patients with abnormal liver function, those receiving higher doses, and patients with non-small cell lung cancer and a history of prior treatment with platinum derivatives who receive single-agent docetaxel at a dose of 100 mg/m<sup>2</sup>.</p>
<p style="text-indent:-2em;margin-left:4em;">• Tumor lysis syndrome: Tumor lysis syndrome (TLS) has occurred; closely monitor patients at high risk of TLS (eg, renal impairment, hyperuricemia, bulky tumor) prior to therapy and periodically during therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Weakness: Fatigue and weakness (may be severe) have been reported; symptoms may last a few days up to several weeks. In patients with progressive disease, weakness may be associated with a decrease in performance status.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Heart failure: In a scientific statement from the American Heart Association, docetaxel has been determined to be an agent that may either cause direct myocardial toxicity or exacerbate underlying myocardial dysfunction (magnitude: moderate) (AHA [Page 2016]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Patients with bilirubin elevations or abnormal transaminases (with concurrent abnormal alkaline phosphatase) are at increased risk for severe neutropenia, neutropenic fever, infections, severe thrombocytopenia, severe stomatitis, severe skin toxicity, and toxic death. Patients with isolated transaminase elevations &gt;1.5 times ULN also had a higher rate of neutropenic fever.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Alcohol content: Some docetaxel formulations contain alcohol (content varies by formulation), which may affect the central nervous system and cause symptoms of alcohol intoxication. Consider alcohol content and use with caution in patients for whom alcohol intake should be avoided or minimized. Patients should avoid driving or operating machinery immediately after the infusion. An FDA-approved non-alcohol generic formulation (20 mg/mL) is available.</p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p></div>
<div class="block dosfc drugH1Div" id="F46044272"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:0em;display:inline">Non-alcohol formulation (Eagle/Teikuku pharmaceuticals): Solution, Intravenous [alcohol-free]: Generic: 20 mg/mL (1 mL; single-dose vial); 80 mg/4 mL (4 mL multi-dose vial); 160 mg/8 mL (8 mL; multi-dose vial)</p></div>
<div class="block foc drugH1Div" id="F162028"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Concentrate, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Taxotere: 20 mg/mL (1 mL [DSC]) [contains alcohol, usp, polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 20 mg/mL (1 mL); 80 mg/4 mL (4 mL); 160 mg/8 mL (8 mL); 200 mg/10 mL (10 mL [DSC])</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Concentrate, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 20 mg/mL (1 mL); 160 mg/8 mL (8 mL [DSC])</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 20 mg/2 mL (2 mL); 80 mg/8 mL (8 mL); 160 mg/16 mL (16 mL)</p></div>
<div class="block geq drugH1Div" id="F162014"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16323117"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Concentrate</b> (DOCEtaxel Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg/mL (per mL): $26.40 - $365.15</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">80 mg/4 mL (per mL): $23.40 - $365.15</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">160 mg/8 mL (per mL): $25.50 - $365.15</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (DOCEtaxel Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg/2 mL (per mL): $26.40 - $194.31</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">80 mg/8 mL (per mL): $24.00 - $189.77</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">160 mg/16 mL (per mL): $20.48 - $189.77</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866646"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Concentrate, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Taxotere: 80 mg/2 mL ([DSC]) [contains alcohol, usp, polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 20 mg/mL (1 mL, 4 mL, 8 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg/mL (2 mL, 8 mL, 16 mL)</p></div>
<div class="block adm drugH1Div" id="F162031"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>IV:</b> Infuse over 1 hour through nonsorbing polyethylene lined (non-DEHP) tubing. <b>Note:</b> Premedication with corticosteroids for 3 days, beginning the day before docetaxel administration, is recommended to reduce the incidence and severity of hypersensitivity reactions and fluid retention (see "Dosing: Adult" for premedication information). Monitor for hypersensitivity reactions, especially during the first and second infusion. Some docetaxel formulations contain alcohol (content varies by formulation); use with caution in patients for whom alcohol intake should be avoided or minimized (a non-alcohol generic formulation [20 mg/mL] is also available).</p>
<p style="text-indent:0em;margin-top:2em;">The use of an in-line filter is not necessary during administration of the Taxotere brand; according to the manufacturer, studies have not been performed to determine the compatibility of IV filters for administration and filters are not recommended for use with docetaxel (data on file [Sanofi Aventis 2016]). The use of an inline filter is also not recommended for administration of the non-alcohol docetaxel formulation (data on file [Eagle Pharmaceuticals 2016]).</p>
<p style="text-indent:0em;margin-top:2em;">Irritant with vesicant-like properties; avoid extravasation. Assure proper needle or catheter position prior to administration.</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Extravasation management:</b> If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); remove needle/cannula; elevate extremity. Information conflicts regarding the use of warm or cold compresses (Perez Fidalgo 2012; Polovich 2009).</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Intravesicular administration for non–muscle invasive bladder cancer (off-label use):</b> Empty bladder prior to docetaxel instillation; instruct patient to retain for 1 to 2 hours (based on protocol) and then empty bladder (Barlow 2009; Barlow 2013; McKiernan 2006; Milbar 2017; Steinberg 2015; Steinberg 2020).</p></div>
<div class="block admp drugH1Div" id="F52612606"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Administer as an IV infusion over 1 hour through nonsorbing polyethylene-lined (non-DEHP) tubing; in-line filter is not necessary (the use of a filter during administration is not recommended by the manufacturer). Infusion should be completed within 4 hours of preparation. <b>Note:</b> Premedication with corticosteroids for 3 days, beginning the day before docetaxel administration, is recommended to prevent hypersensitivity reactions and pulmonary/peripheral edema. Some docetaxel formulations contain alcohol (content varies by formulation); use with caution in patients for whom alcohol intake should be avoided or minimized.</p>
<p style="text-indent:-2em;margin-left:2em;">Irritant with vesicant-like properties; avoid extravasation. Assure proper needle or catheter position prior to administration. If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); remove needle/cannula; elevate extremity. Information conflicts regarding the use of warm or cold compresses (Pérez Fidalgo 2012; Polovich 2009).</p></div>
<div class="block hazard drugH1Div" id="F49130975"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 1]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p></div>
<div class="block use drugH1Div" id="F162029"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Breast cancer:</b> Treatment of breast cancer (locally advanced/metastatic) after prior chemotherapy failure; adjuvant treatment (in combination with doxorubicin and cyclophosphamide) of operable node-positive breast cancer.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Gastric adenocarcinoma:</b> Treatment of advanced gastric adenocarcinoma, including gastroesophageal junction adenocarcinoma (in combination with cisplatin and fluorouracil) in patients who have not received prior chemotherapy for advanced disease.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Head and neck cancer:</b> Treatment (induction) of locally advanced squamous cell head and neck cancer (in combination with cisplatin and fluorouracil).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Non-small cell lung cancer:</b> Treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure of prior platinum-based chemotherapy; treatment of previously untreated unresectable locally advanced or metastatic NSCLC (in combination with cisplatin).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Prostate cancer:</b> Treatment of metastatic castration-resistant prostate cancer (in combination with prednisone).</p></div>
<div class="block off-label drugH1Div" id="F25475018"><span class="drugH1">Use: Off-Label: Adult</span><p>Anal carcinoma (squamous cell), advanced; Bladder cancer, advanced or metastatic; Bladder cancer, non–muscle invasive, refractory (intravesical); Esophageal cancer, chemoradiation; Esophageal cancer, locally advanced or metastatic disease; Ewing sarcoma (recurrent or refractory); Osteosarcoma (recurrent or refractory); Ovarian cancer; Prostate cancer, metastatic, hormone-sensitive; Small cell lung cancer, relapsed; Soft tissue sarcoma (recurrent or progressive); Thyroid carcinoma, anaplastic; Unknown primary, adenocarcinoma; Uterine leiomyosarcoma (advanced or high-grade)</p></div>
<div class="block mst drugH1Div" id="F162103"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">DOCEtaxel may be confused with cabazitaxel, PACLitaxel (conventional), PACLitaxel (protein bound).</p>
<p style="text-indent:-2em;margin-left:4em;">Taxotere [DSC] may be confused with Abraxane, Taxol.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Administration issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Multiple concentrations: Docetaxel is available as a one-vial formulation at concentrations of 10 mg/mL (generic formulation) and 20 mg/mL (concentrate/solution; Taxotere or non-alcohol generic formulation). Admixture errors have occurred due to the availability of various docetaxel concentrations.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F162087"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (major), OATP1B1/1B3 (SLCO1B1/1B3), P-glycoprotein/ABCB1 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F162022"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anthracyclines: Taxane Derivatives may enhance the adverse/toxic effect of Anthracyclines. Taxane Derivatives may increase the serum concentration of Anthracyclines. Taxane Derivatives may also increase the formation of toxic anthracycline metabolites in heart tissue.  Management: Consider separating doxorubicin and paclitaxel administration by as much time as possible, using liposomal doxorubicin or epirubicin instead of doxorubicin, or using docetaxel instead of paclitaxel. Monitor closely for cardiovascular and other toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of cytotoxic chemotherapy is reduced. Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of BCG Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing cytotoxic chemotherapy several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Adenovirus Vector): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector).  Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Inactivated Virus): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Inactivated Virus). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (mRNA): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (mRNA).  Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Subunit): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Subunit). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Virus-like Particles): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Virus-like Particles). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of DOCEtaxel.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of DOCEtaxel.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of DOCEtaxel. Management: Avoid the concomitant use of docetaxel and strong CYP3A4 inhibitors when possible. If combined use is unavoidable, consider a 50% docetaxel dose reduction and monitor for increased docetaxel toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone.  Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy). Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and cytotoxic chemotherapy. If combined, monitor patients for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dronedarone: May increase the serum concentration of DOCEtaxel. Management: Avoid this combination whenever possible. If this combination must be used, consider using a reduced docetaxel dose, and/or increase monitoring for evidence of serious docetaxel toxicity (e.g., neutropenia, mucositis, hepatotoxicity etc.).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines at least 2 weeks prior to initiating chemotherapy if possible. If vaccination occurs less than 2 weeks prior to or during chemotherapy, revaccinate at least 3 months after therapy discontinued if immune competence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents, such as cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim.  Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim.  Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: Myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Platinum Derivatives: May enhance the myelosuppressive effect of Taxane Derivatives. Administer Taxane derivative before Platinum derivative when given as sequential infusions to limit toxicity. Management: Administer paclitaxel before cisplatin, when given as sequential infusions, to limit toxicity. Problems associated with other taxane/platinum combinations are possible, although unsubstantiated. Administering the taxane before platinum is likely warranted<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Pneumococcal Vaccines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: Myelosuppressive Agents may enhance the myelosuppressive effect of Ropeginterferon Alfa-2b.  Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants, such as cytotoxic chemotherapy, prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">SORAfenib: May increase the serum concentration of DOCEtaxel.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Tofacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Upadacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Give inactivated vaccines at least 2 weeks prior to initiation of chemotherapy when possible. Patients vaccinated less than 14 days before initiating or during chemotherapy should be revaccinated at least 3 months after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Vaccines (Live) may diminish the therapeutic effect of Immunosuppressants (Cytotoxic Chemotherapy). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F49298498"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Evaluate pregnancy status prior to use in patients who could become pregnant. Patients who could become pregnant should use effective contraceptive measures before beginning treatment, during therapy, and for 2 months after the last docetaxel dose. Patients with partners who could become pregnant should use effective contraceptives during therapy and for 4 months after the last docetaxel dose.</p></div>
<div class="block pri drugH1Div" id="F162037"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">An ex vivo human placenta perfusion model illustrated that docetaxel crossed the placenta at term. Placental transfer was low and affected by the presence of albumin; higher albumin concentrations resulted in lower docetaxel placental transfer (Berveiller 2012).</p>
<p style="text-indent:0em;margin-top:2em;">Based on the mechanism of action and data from animal reproduction studies, in utero exposure to docetaxel may cause fetal harm. Formulations may contain alcohol, which is also associated with adverse fetal effects.</p>
<p style="text-indent:0em;margin-top:2em;">Some pharmacokinetic properties of docetaxel may be altered in pregnant women (van Hasselt 2014). Data related to the use of docetaxel for the treatment of breast cancer in pregnancy is limited. Use should be restricted for clinically urgent situations; use of other agents is preferred. The European Society for Medical Oncology has published guidelines for diagnosis, treatment, and follow-up of cancer during pregnancy; the guidelines recommend referral to a facility with expertise in cancer during pregnancy and encourage a multidisciplinary team (obstetrician, neonatologist, oncology team). In general, if chemotherapy is indicated, it should be avoided in the first trimester and there should be a 3-week time period between the last chemotherapy dose and anticipated delivery, and chemotherapy should not be administered beyond week 33 of gestation (ESMO [Peccatori 2013]).</p>
<p style="text-indent:0em;margin-top:2em;">A pregnancy registry is available for all cancers diagnosed during pregnancy at Cooper Health (877-635-4499).</p></div>
<div class="block brc drugH1Div" id="F162038"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if docetaxel is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in breastfed infants, breastfeeding is not recommended by the manufacturer during treatment and for 1 week after the last docetaxel dose.</p></div>
<div class="block mop drugH1Div" id="F162026"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">CBC with differential (prior to each cycle; monitor frequently in patients with hematologic toxicity), LFTs (bilirubin, ALT, AST, alkaline phosphatase; prior to each cycle; more frequently if clinically indicated), renal function. Evaluate pregnancy status prior to use in patients who could become pregnant. Monitor for hypersensitivity reactions (particularly with the first and second infusion; patients with a history of paclitaxel hypersensitivity require close monitoring during initiation). Monitor for signs/symptoms of neurosensory symptoms, GI toxicity (eg, diarrhea, stomatitis, enterocolitis, neutropenic colitis), cutaneous reactions or severe skin toxicity, visual impairment, fluid retention (patients with existing effusions should be monitored closely during the first infusion for potential exacerbation), epiphora, canalicular stenosis, tumor lysis syndrome (prior to initiation and periodically during therapy), and second primary malignancies. A prompt comprehensive ophthalmic exam is recommended if vision impairment occurs.</p>
<p style="text-indent:-2em;margin-left:2em;">The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.</p></div>
<div class="block pha drugH1Div" id="F162017"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Docetaxel promotes the assembly of microtubules from tubulin dimers, and inhibits the depolymerization of tubulin which stabilizes microtubules in the cell. This results in inhibition of DNA, RNA, and protein synthesis. Most activity occurs during the M phase of the cell cycle.</p></div>
<div class="block phk drugH1Div" id="F162033"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>dss </sub>(mean): 113 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ~94% to 97%, primarily to alpha<sub>1</sub>-acid glycoprotein, albumin, and lipoproteins.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic; oxidation via CYP3A4 to metabolites.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Terminal (mean): 116 hours (range: 92 to 135 hours).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces (~75%, &lt;8% as unchanged drug); urine (~6%).</p>
<p style="text-indent:-2em;margin-left:4em;">Clearance (mean): 18 L/hour/m<sup>2</sup>.</p></div>
<div class="block phksp drugH1Div" id="F51153967"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: Total body clearance is reduced by average of 27% and AUC increased 38% in patients with mild to moderate hepatic function impairment (ALT and/or AST more than 1.5 × ULN concomitant with alkaline phosphatase more than 2.5 × ULN).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F2869377"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Taxotere</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Asodocel | Docetaxel delta farma | Docetaxel fada | Docetaxel gobbi | Docetaxel tuteur | Eriox | Imaxel | Taxotere rtu</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Docetaxel accord | Docetaxel ebewe | Docetaxel haemato | Docetaxel hospira | Docetaxel kabi | Docetaxel ratiopham | Docetaxel stada | Ebedoce | Onkotaxel | Taxotere</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">As Docetaxel | DBL docetaxel | Docetaxel accord | Docetaxel ebewe | Docetaxel sandoz | Dotax | Taxotere</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Docetaxel accord | Docetaxel actavis | Docetaxel ebewe pharma | Docetaxel EG | Docetaxel hospira | Docetaxel kabi | Docetaxel ratiopharm | Docetaxel sandoz | Docirena | Taxotere</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Taxotere</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Docetax | Docetaxel actavis | Docetaxel aqvida | Docetaxel bulgermed | Docetaxel hospira | Docetaxel kabi | Docetaxel novamed | Taxotere | Tolnexa</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Doceglennu | Docelibbs | Docetaxel tri hidratado | Docetere | Doceuno | Dosataxel | Neotaxel | Oncodocel | Tace | Taxotere | Trixotene</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Docetaxel accord | Docetaxel actavis | Docetaxel fresenius | Docetaxel labatec | Docetaxel mepha | Docetaxel sandoz | Docetaxel teva | Docetaxel Zentiva | Taxotere</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Docetaxel cooper | Lexus | Taxotere</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Taxespira | Taxotere</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Duo pa fei | Taxotere</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Docetaxel sandoz | Dotaxel | Labdosa plustaxano | Oncodocel | Oncotaxel | Soulaxin | Taxespira | Taxotere</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Docetaxel accord | Docetaxel actavis | Docetaxel ebewe | Docetaxel hospira | Docetaxel kabi | Docetaxel teva | Taxegis | Taxotere | Tolnexa</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Bendadocel | Doce nc | Doce Onkovis | Docetaxel accord | Docetaxel actavis | Docetaxel amneal | Docetaxel aqvida | Docetaxel aurobindo | Docetaxel axios | Docetaxel beta | Docetaxel cell pharm | Docetaxel haemato | Docetaxel Hexal | Docetaxel hospira | Docetaxel kabi | Docetaxel NC | Docetaxel Omnicare | Docetaxel Oncotrade | Docetaxel Profusio | Docetaxel ratiopharm | Docetaxel ribosepharm | Docetaxel stada | Docetaxel teva | Docetaxel tillomed | Docetaxel vipharm | Docetaxel Zentiva | Docetaxin | Docirena | Eurodocetaxel | Eurotere | Ribodocel | Taxceus | Taxotan | Taxotere</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Daxotel | Docetaxel lam | Doxel</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Docetaxel accord | Docetaxel ebewe | Docetaxel hospira | Docetaxel kabi | Docetaxel teva | Taxotere</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Daxotel | Docetaxel ebewe | Docetaxel filaxis | Docetaxel kabi | Taxotere</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Docetaxel accord | Docetaxel actavis | Docetaxel aurovitas | Docetaxel ebewe | Docetaxel hospira | Docetaxel kabi | Docetaxel pfizer | Docetaxel teva | Taxotere</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">D tail | Taxotere</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Docetaxel accord | Docetaxel hospira | Docetaxel nordic | Docetaxel pfizer | Taxotere</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Docetaxel accord | Docetaxel actavis | Docetaxel ebewe | Docetaxel hospira | Docetaxel kabi | Docetaxel teva</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Docetaxel hospira | Docetaxel sandoz | Docetaxel teva | Taxceus | Taxotere</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Aritaxel | Demotaxel mono | Docetaxel accord | Docetaxel kabi | Docetaxel/actavis | Docetaxel/hospira | Docetaxel/medicalis | Doxen | Taxotere | Taxovina | Zakotax</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Docetaxel ebewe | Hospira docetaxel | Taxotere</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Docetaksel Actavis | Docetaksel Belupo | Docetaksel Pliva | Docetaxel accord | Docetaxel hospira | Docetaxel kabi | Taxotere | Tolnexa</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Camitotic | Docetaxel accord | Docetaxel ebewe | Docetaxel kabi | Docetaxel medico uno | Docetaxel Pharmacenter | Docetaxel teva | Docetaxel venus pharma | Docirena | Taxegis | Taxotere | Tolnexa</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Brexel | Daxotel | Docetaxel ebewe | Doxetasan | Taxotere</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Docetaxel kabi | Taxotere</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Taxotere</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Celtere | Chemodoc | Daxotel | Docax | Docetax | Docezap | Dtaxane | Stridotere | Taxogem | Taxotere | Zytax</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Docetaxel accord | Docetaxel Acvavis | Docetaxel hikma | Docetaxel hospira | Docetaxel sandoz | Docetaxel teva | Taxceus | Taxotere</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Docelina | Taxotere</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Onetaxotere | Taxotere aventis | Taxotere chugai</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Adoxi | Celtere | D tail | Daxotel | Docecord | Taxotere</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Belotaxel 1 | Ditaxel | Ditaxel1 | Docel | Dong a pharm docetaxel anhydrous | Dotaxel | Doxotel | Monotaxel | Newtaxel a | Pacancer | Taxelo | Taxotere | Taxotere1 | Taxozen | Taxozen 1 | Verotaxel</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Taxotere</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Docetax | Docetaxel hospira | Taxotere</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Camitotic | Docetaxel accord | Docetaxel actavis | Docetaxel ebewe | Docetaxel hospira | Docetaxel kabi | Docetaxel Mylan | Docetaxel sanoswiss | Docetaxel teva | Taxotere | Tolnexa</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Camitotic | Docetaxel accord | Docetaxel actavis | Docetaxel hospira | Docetaxel kabi | Docetaxel teva | Taxotere | Tolnexa</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Docetaxel cooper | Docetaxel zenith | Taxotere</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Aracet | Asodoc | Bindu | Datilev | Daxel | Miocerkel | Prosaglic | Somatixel | Soulaxin | Taxagentec | Taxanit | Taxanit rtu | Taxespira | Taxulide | Zurixol</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Docetax | Taxotere | Taxtas</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Taxotere | Taxotex</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Docetaxel accord | Docetaxel actavis | Docetaxel hospira | Docetaxel sandoz | Docetaxel seacross | Docetaxel teva | Docirena | Taxotere</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Docetaxel accord | Docetaxel hospira | Docetaxel kabi | Docetaxel teva | Taxotere</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">DBL docetaxel | Docetaxel accord | Docetaxel sandoz</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Taxomed | Taxotere</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Biomedis docetaxel | Daxotel | Doxestad | Hentaxel | Hospira docetaxel | Newtaxel a | Oncotaxel | Taceedo | Taxewell | Vexdo</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Daxotel | Docetax | Docetaxel aqvida | Docetaxel varifarma | Donataxel | Ebedoce | Mebrexel | Taxotere | Texot</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Daxtere | Docetaxel accord | Docetaxel ebewe | Docetaxel hospira | Docetaxel kabi | Docetaxel teva | Taxotere</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Taxotere</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Docetaxel actavis | Docetaxel hikma | Docetaxel kabi | Docetaxel sandoz | Docetaxel teva | Qvidadotax | Taxotere</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Docetaxel 80 richmond | Docetaxel demotek | Docetaxel microsules | Docetaxel sandoz | Docetaxel tuteur | Doxel | Oncodocel | Taxotere</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Taxotere</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Docetaxel accord | Docetaxel actavis | Docetaxel ebewe | Docetaxel hospira | Docetaxel kabi | Docetaxel teva | Docirena | Tolnexa</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Docetaxel filaxis | Docetaxel kelun kazpharm | Docetaxel Rus | Docetaxel sandoz | Docetera | Novotax | Oncodocel | Tautax | Taxelen | Taxotere</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Docetaxel spc</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Docetaxel accord | Docetaxel actavis | Docetaxel amring | Docetaxel ebewe | Docetaxel hospira | Docetaxel kabi | Docetaxel teva | Taxotere</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Taxotere</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Docetaksel accord | Docetaksel Ebewe | Docetaksel Kabi | Docetaxel teva | Taxotere</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Camitotic | Docetaxel accord | Docetaxel ebewe | Docetaxel egis | Docetaxel hospira | Docetaxel kabi | Docetaxel sandoz | Docetaxel teva | Taxegis | Taxotere | Tolnexa</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Daxotel | Docegrix | Docetaxel hospira | Donataxel | Dotax | Oncotaxel | Taxotere</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Cytotere | Docetaxel hospira | Taxotere</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Docetu | Docexus | Doxel | Doxel ready | Doxitax | Doxitax Tec | Santax | Tadocel | Taxotere</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Daxotel | Doce | Dofor | Isotera | Nolbaxol | Phyxotere | Taxotere | Tynen | Tyxan</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Docemeda | Docet | Docetactin | Docetax | Docetaxel accord | Docetaxel krka | Docetaxelum | Docetera | Doxtored | Taxolik | Taxotere</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Oncodocel</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Taxotere</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Axtere | Cipla docetaxel | Docetaxel accord | Docetaxel adco | Docetaxel Cipla | Docetaxel key | Docetere | Doxel | Taxocan | Taxotere</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Taxotere rtu</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Taxotere</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  &lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary</i> (USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16110025">
<a name="16110025"></a>Ajani JA, Fodor MD, Tjulandin SA, et al, “Phase II Multi-Institutional Randomized Trial of Docetaxel Plus Cisplatin With or Without Fluorouracil in Patients With Untreated, Advanced Gastric, or Gastroesophageal Adenocarcinoma,” <i>J Clin Oncol</i>, 2005, 23(24):5660-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/16110025/pubmed" id="16110025" target="_blank">16110025</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17664467">
<a name="17664467"></a>Ajani JA, Moiseyenko VM, Tjulandin S, et al, “Clinical Benefit With Docetaxel Plus Fluorouracil and Cisplatin Compared With Cisplatin and Fluorouracil in a Phase III Trial of Advanced Gastric or Gastroesophageal Cancer Adenocarcinoma: The V-325 Study Group,” <i>J Clin Oncol</i>, 2007, 25(22):3205-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/17664467/pubmed" id="17664467" target="_blank">17664467</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18669868">
<a name="18669868"></a>Al-Batran SE, Hartmann JT, Hofheinz R, et al. Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. <i>Ann Oncol</i>. 2008;19(11):1882-1887. doi:10.1093/annonc/mdn403<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/18669868/pubmed" id="18669868" target="_blank">18669868</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30982686">
<a name="30982686"></a>Al-Batran SE, Homann N, Pauligk C, et al; FLOT4-AIO Investigators. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. <i>Lancet</i>. 2019;393(10184):1948-1957. doi:10.1016/S0140-6736(18)32557-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/30982686/pubmed" id="30982686" target="_blank">30982686</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23649003">
<a name="23649003"></a>Aparicio AM, Harzstark AL, Corn PG, et al. Platinum-based chemotherapy for variant castrate-resistant prostate cancer. <i>Clin Cancer Res</i>. 2013;19(13):3621-3630. doi:10.1158/1078-0432.CCR-12-3791<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/23649003/pubmed" id="23649003" target="_blank">23649003</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23123371">
<a name="23123371"></a>Barlow LJ, McKiernan JM, Benson MC. Long-term survival outcomes with intravesical docetaxel for recurrent nonmuscle invasive bladder cancer after previous bacillus Calmette-Guérin therapy. <i>J Urol.</i> 2013;189(3):834-839. doi:10.1016/j.juro.2012.10.068<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/23123371/pubmed" id="23123371" target="_blank">23123371</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19214528">
<a name="19214528"></a>Barlow LJ, McKiernan JM, Benson MC. The novel use of intravesical docetaxel for the treatment of non-muscle invasive bladder cancer refractory to BCG therapy: a single institution experience. <i>World J Urol</i>. 2009;27(3):331-335. doi:10.1007/s00345-009-0377-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/19214528/pubmed" id="19214528" target="_blank">19214528</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25199761">
<a name="25199761"></a>Basch E, Loblaw DA, Oliver TK, et al. Systemic Therapy in Men With Metastatic Castration-Resistant Prostate Cancer: American Society of Clinical Oncology and Cancer Care Ontario Clinical Practice Guideline [published online ahead of print September 8, 2014]. <i>J Clin Oncol</i>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/25199761/pubmed" id="25199761" target="_blank">25199761</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22149875">
<a name="22149875"></a>Baselga J, Cortés J, Kim SB, et al, “Pertuzumab Plus Trastuzumab Plus Docetaxel for Metastatic Breast Cancer,” <i>N Engl J Med</i>, 2012, 366(2):109-19.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/22149875/pubmed" id="22149875" target="_blank">22149875</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23174392">
<a name="23174392"></a>Berveiller P, Vinot C, Mir O, et al, "Comparative Transplacental Transfer of Taxanes Using the Human Perfused Cotyledon Placental Model," <i>Am J Obstet Gynecol</i>, 2012, 207(6):514.e1-514.e7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/23174392/pubmed" id="23174392" target="_blank">23174392</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20089562">
<a name="20089562"></a>Blohmer JU, Schmid P, Hilfrich J, et al, “Epirubicin and Cyclophosphamide Versus Epirubicin and Docetaxel as First-Line Therapy for Women With Metastatic Breast Cancer: Final Results of a Randomised Phase III Trial,” <i>Ann Oncol</i>, 2010, 21(7):1430-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/20089562/pubmed" id="20089562" target="_blank">20089562</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10715290">
<a name="10715290"></a>Burstein HJ, Manola J, Younger J, et al, “Docetaxel Administered on a Weekly Basis for Metastatic Breast Cancer,” <i>J Clin Oncol</i>, 2000, 18(6):1212-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/10715290/pubmed" id="10715290" target="_blank">10715290</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23650421">
<a name="23650421"></a>Chan A, Su C, de Boer RH, Gajdatsy A. Prevalence of excessive tearing in women with early breast cancer receiving adjuvant docetaxel-based chemotherapy. <i>J Clin Oncol</i>. 2013;31(17):2123-2127. doi: 10.1200/JCO.2012.45.6574.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/23650421/pubmed" id="23650421" target="_blank">23650421</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10561296">
<a name="10561296"></a>Chan S, Friedrichs K, Noel D, et al; 303 Study Group. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. <i>J Clin Oncol.</i> 1999;17(8):2341-2354. doi:10.1200/JCO.1999.17.8.2341<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/10561296/pubmed" id="10561296" target="_blank">10561296</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21157450">
<a name="21157450"></a>Day FL, Leong T, Ngan S, et al, “Phase I Trial of Docetaxel, Cisplatin and Concurrent Radical Radiotherapy in Locally Advanced Oesophageal Cancer,” <i>Br J Cancer</i>, 2011, 104(2):265-71.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/21157450/pubmed" id="21157450" target="_blank">21157450</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9671871">
<a name="9671871"></a>Dimopoulos MA, Deliveliotis C, Moulopoulos LA, et al. Treatment of patients with metastatic urothelial carcinoma and impaired renal function with single-agent docetaxel. <i>Urology</i>. 1998;52(1):56-60. doi:10.1016/s0090-4295(98)00150-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/9671871/pubmed" id="9671871" target="_blank">9671871</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Docetaxel injection [prescribing information]. E. Windsor, NJ: AuroMedics Pharma LLC; February 2021.</div>
</li>
<li>
<div class="reference">
                  Docetaxel injection [prescribing information]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc; December 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Docetaxel.3">
<a name="Docetaxel.3"></a>Docetaxel injection [product monograph]. Kirkland, Quebec, Canada: Sandoz Canada Inc; June 2023.</div>
</li>
<li>
<div class="reference">
                  Docetaxel injection (non-alcohol formula) [prescribing information]. Burlington, MA: AMRI Burlington Inc; August 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23512831">
<a name="23512831"></a>Dupuis LL, Boodhan S, Holdsworth M, et al. Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patient. <i>Pediatr Blood Cancer</i>. 2013;60(7):1073-1082.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/23512831/pubmed" id="23512831" target="_blank">23512831</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21465637">
<a name="21465637"></a>Dupuis LL, Boodhan S, Sung L, et al; Pediatric Oncology Group of Ontario. Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients. <i>Pediatr Blood Cancer</i>. 2011;57(2):191-198.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/21465637/pubmed" id="21465637" target="_blank">21465637</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11919237">
<a name="11919237"></a>Esteva FJ, Valero V, Booser D, et al, “Phase II Study of Weekly Docetaxel and Trastuzumab for Patients With HER-2-Overexpressing Metastatic Breast Cancer,” <i>J Clin Oncol</i>, 2002, 20(7):1800-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/11919237/pubmed" id="11919237" target="_blank">11919237</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35405085">
<a name="35405085"></a>Fizazi K, Foulon S, Carles J, et al; PEACE-1 investigators. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design. <i>Lancet</i>. 2022;399(10336):1695-1707. doi:10.1016/S0140-6736(22)00367-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/35405085/pubmed" id="35405085" target="_blank">35405085</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16473644">
<a name="16473644"></a>Floyd J, Mirza I, Sachs B, et al, “Hepatotoxicity of Chemotherapy,” <i>Semin Oncol</i>, 2006, 33(1):50-67.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/16473644/pubmed" id="16473644" target="_blank">16473644</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16234530">
<a name="16234530"></a>Floyd JD, Nguyen DT, Lobins RL, et al, “Cardiotoxicity of Cancer Therapy,” <i>J Clin Oncol</i>, 2005, 23(30):7685-96.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/16234530/pubmed" id="16234530" target="_blank">16234530</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21162687">
<a name="21162687"></a>Foote RL, Molina JR, Kasperbauer JL, et al. Enhanced survival in locoregionally confined anaplastic thyroid carcinoma: a single-institution experience using aggressive multimodal therapy. <i>Thyroid</i>. 2011;21(1):25-30. doi:10.1089/thy.2010.0220<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/21162687/pubmed" id="21162687" target="_blank">21162687</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12837811">
<a name="12837811"></a>Fossella F, Pereira JR, von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. <i>J Clin Oncol.</i> 2003;21(16):3016-3024. doi:10.1200/JCO.2003.12.046<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/12837811/pubmed" id="12837811" target="_blank">12837811</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10856094">
<a name="10856094"></a>Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. <i>J Clin Oncol</i>. 2000;18(12):2354-2362. doi:10.1200/JCO.2000.18.12.2354<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/10856094/pubmed" id="10856094" target="_blank">10856094</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22363068">
<a name="22363068"></a>Fox E, Patel S, Wathen JK, et al. Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: results of Sarcoma Alliance for Research Through Collaboration Study 003. <i>Oncologist</i>. 2012;17(3):321. doi:10.1634/theoncologist.2010-0265<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/22363068/pubmed" id="22363068" target="_blank">22363068</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17762444">
<a name="17762444"></a>Garcia AA, Blessing JA, Vaccarell L, et al, “Phase II Clinical Trial of Docetaxel in Refractory Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study,” <i>Am J Clin Oncol</i>, 2007, 30(4):428-31.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/17762444/pubmed" id="17762444" target="_blank">17762444</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24933332">
<a name="24933332"></a>Garon EB, Ciuleanu TE, Arrieta O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicenter, double-blind, randomized phase 3 trial. <i>Lancet</i>. 2014;384(9944):665-673. doi:10.1016/S0140-6736(14)60845-X<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/24933332/pubmed" id="24933332" target="_blank">24933332</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22469940">
<a name="22469940"></a>George SL, Broster S, Chisholm JC, Brock P. Docetaxel in the treatment of children with refractory or relapsed hepatoblastoma. <i>J Pediatr Hematol Oncol</i>. 2012;34(7):e295-297.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/22469940/pubmed" id="22469940" target="_blank">22469940</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22153890">
<a name="22153890"></a>Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. <i>Lancet Oncol</i>. 2012;13(1):25-32.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/22153890/pubmed" id="22153890" target="_blank">22153890</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10761758">
<a name="10761758"></a>Greco FA, Erland JB, Morrissey LH, et al, “Carcinoma of Unknown Primary Site: Phase II Trials With Docetaxel Plus Cisplatin or Carboplatin,” <i>Ann Oncol</i>, 2000, 11(2):211-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/10761758/pubmed" id="10761758" target="_blank">10761758</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33939491">
<a name="33939491"></a>Griggs JJ, Bohlke K, Balaban EP, et al. Appropriate systemic therapy dosing for obese adult patients with cancer: ASCO guideline update. <i>J Clin Oncol</i>. 2021;39(18):2037-2048. doi:10.1200/JCO.21.00471<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/33939491/pubmed" id="33939491" target="_blank">33939491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17033039">
<a name="17033039"></a>Harvey V, Mouridsen H, Semiglazov V, et al, “Phase III Trial Comparing Three Doses of Docetaxel For Second-Line Treatment of Advanced Breast Cancer,” <i>J Clin Oncol</i>, 2006, 24(31):4963-4970.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/17033039/pubmed" id="17033039" target="_blank">17033039</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19135708">
<a name="19135708"></a>Hensley ML, Ishill N, Soslow R, et al. Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: results of a prospective study. <i>Gynecol Oncol</i>. 2009;112(3):563-567. doi:10.1016/j.ygyno.2008.11.027<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/19135708/pubmed" id="19135708" target="_blank">19135708</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12065559">
<a name="12065559"></a>Hensley ML, Maki R, Venkatraman E, et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. <i>J Clin Oncol.</i> 2002;20(12):2824-2831. doi:10.1200/JCO.2002.11.050<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/12065559/pubmed" id="12065559" target="_blank">12065559</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25713428">
<a name="25713428"></a>Hensley ML, Miller A, O'Malley DM, et al. Randomized phase III trial of gemcitabine plus docetaxel plus bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma: an NRG Oncology/Gynecologic Oncology Group study. <i>J Clin Oncol.</i> 2015;33(10):1180-1185. doi:10.1200/JCO.2014.58.3781<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/25713428/pubmed" id="25713428" target="_blank">25713428</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16935890">
<a name="16935890"></a>Hochegger K, Lhotta K, Mayer G, Czejka M, Hilbe W. Pharmacokinetic analysis of docetaxel during haemodialysis in a patient with locally advanced non-small cell lung cancer. <i>Nephrol Dial Transplant</i>. 2007;22(1):289-290. doi:10.1093/ndt/gfl498<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/16935890/pubmed" id="16935890" target="_blank">16935890</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19064973">
<a name="19064973"></a>Hui EP, Ma BB, Leung SF, et al. Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. <i>J Clin Oncol.</i> 2009;27(2):242-249. doi:10.1200/JCO.2008.18.1545<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/19064973/pubmed" id="19064973" target="_blank">19064973</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26719232">
<a name="26719232"></a>James ND, Sydes MR, Clarke NW, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387(10024):1163-77.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/26719232/pubmed" id="26719232" target="_blank">26719232</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20118214">
<a name="20118214"></a>Janus N, Thariat J, Boulanger H, Deray G, Launay-Vacher V. Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients. <i>Ann Oncol</i>. 2010;21(7):1395-1403. doi:10.1093/annonc/mdp598<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/20118214/pubmed" id="20118214" target="_blank">20118214</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22795584">
<a name="22795584"></a>Ji JH; Korean Cancer Study Group (KCSG), Yun T, Kim SB, et al, “A Prospective Multicentre Phase II Study of Cisplatin and Weekly Docetaxel as First-Line Treatment for Recurrent or Metastatic Nasopharyngeal Cancer (KCSG HN07-01),” <i>Eur J Cancer</i>, 2012, 48(17):3198-204.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/22795584/pubmed" id="22795584" target="_blank">22795584</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19204201">
<a name="19204201"></a>Jones S, Holmes FA, O'Shaughnessy J, et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735. <i>J Clin Oncol.</i> 2009;27(8):1177-1183. doi:10.1200/JCO.2008.18.4028<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/19204201/pubmed" id="19204201" target="_blank">19204201</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24007746">
<a name="24007746"></a>Jones SE, Collea R, Paul D, et al. Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study. <i>Lancet Oncol.</i> 2013;14(11):1121-1128. doi:10.1016/S1470-2045(13)70384-X<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/24007746/pubmed" id="24007746" target="_blank">24007746</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17135639">
<a name="17135639"></a>Jones SE, Savin MA, Holmes FA, et al, "Phase III Trial Comparing Doxorubicin Plus Cyclophosphamide With Docetaxel Plus Cyclophosphamide as Adjuvant Therapy for Operable Breast Cancer," <i>J Clin Oncol</i>, 2006, 24(34):5381-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/17135639/pubmed" id="17135639" target="_blank">17135639</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22334012">
<a name="22334012"></a>Kaneda H, Okamoto I, Nakagawa K. Pharmacokinetics of docetaxel in a patient with non-small cell lung cancer undergoing continuous ambulatory peritoneal dialysis. <i>J Thorac Oncol</i>. 2012;7(3):621-622. doi:10.1097/JTO.0b013e3182460f67<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/22334012/pubmed" id="22334012" target="_blank">22334012</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30042063">
<a name="30042063"></a>Kim S, François E, André T, et al. Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study. <i>Lancet Oncol</i>. 2018;19(8):1094-1106. doi:10.1016/S1470-2045(18)30321-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/30042063/pubmed" id="30042063" target="_blank">30042063</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16716138">
<a name="16716138"></a>Kintzel PE, Michaud LB, Lange MK. Docetaxel-associated epiphora. <i>Pharmacotherapy</i>. 2006 Jun;26(6):853-867.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/16716138/pubmed" id="16716138" target="_blank">16716138</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30942181">
<a name="30942181"></a>Krens SD, Lassche G, Jansman FGA, et al. Dose recommendations for anticancer drugs in patients with renal or hepatic impairment. <i>Lancet Oncol</i>. 2019;20(4):e200-e207. doi:10.1016/S1470-2045(19)30145-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/30942181/pubmed" id="30942181" target="_blank">30942181</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28221727">
<a name="28221727"></a>Kuo C, Kent PM, Logan AD, et al. Docetaxel, bevacizumab, and gemcitabine for very high risk sarcomas in adolescents and young adults: A single-center experience. <i>Pediatr Blood Cancer</i>. 2017;64(4):10.1002/pbc.26265. doi:10.1002/pbc.26265<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/28221727/pubmed" id="28221727" target="_blank">28221727</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17258800">
<a name="17258800"></a>Kushner DM, Connor JP, Sanchez F, et al, “Weekly Docetaxel and Carboplatin for Recurrent Ovarian and Peritoneal Cancer: A Phase II Study,” <i>Gynecol Oncol</i>, 2007, 105(2):358-64.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/17258800/pubmed" id="17258800" target="_blank">17258800</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34357780">
<a name="34357780"></a>Lansinger OM, Biedermann S, He Z, Colevas AD. Do steroids matter? A retrospective review of premedication for taxane chemotherapy and hypersensitivity reactions. <i>J Clin Oncol</i>. 2021;39(32):3583-3590. doi:10.1200/JCO.21.01200<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/34357780/pubmed" id="34357780" target="_blank">34357780</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15117993">
<a name="15117993"></a>Leu KM, Ostruszka LJ, Shewach D, et al, “Laboratory and Clinical Evidence of Synergistic Cytotoxicity of Sequential Treatment With Gemcitabine Followed by Docetaxel in the Treatment of Sarcoma,” <i>J Clin Oncol</i>, 2004, 22(9):1706-12.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/15117993/pubmed" id="15117993" target="_blank">15117993</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19732130">
<a name="19732130"></a>Li QQ, Liu MZ, Hu YH, et al, “Definitive Concomitant Chemoradiotherapy With Docetaxel and Cisplatin in Squamous Esophageal Carcinoma,” <i>Dis Esophagus</i>, 2010, 23(3):253-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/19732130/pubmed" id="19732130" target="_blank">19732130</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17309673">
<a name="17309673"></a>Li YF, Fu S, Hu W, et al, “Systemic Anticancer Therapy in Gynecological Cancer Patients With Renal Dysfunction,” <i>Int J Gynecol Cancer</i>, 2007, 7(4):739-63.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/17309673/pubmed" id="17309673" target="_blank">17309673</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23246022">
<a name="23246022"></a>Mackey JR, Martin M, Pienkowski T, et al, “Adjuvant Docetaxel, Doxorubicin, and Cyclophosphamide in Node-Positive Breast Cancer: 10-Year Follow Up of the Phase III Randomised BCIRG 001 Trial,” <i>Lancet Oncol</i>, 2013, 14(1):72-80.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/23246022/pubmed" id="23246022" target="_blank">23246022</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17602081">
<a name="17602081"></a>Maki RG, Wathen JK, Patel SR, et al, “Randomized Phase II Study of Gemcitabine and Docetaxel Compared With Gemcitabine Alone in Patients With Metastatic Soft Tissue Sarcomas: Results of Sarcoma Alliance for Research Through Collaboration Study 002,” <i>J Clin Oncol</i>, 2007, 25(19):2755-63.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/17602081/pubmed" id="17602081" target="_blank">17602081</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11283121">
<a name="11283121"></a>Markman M, Kennedy A, Webster K, et al, “Combination Chemotherapy With Carboplatin and Docetaxel in the Treatment of Cancers of the Ovary and Fallopian Tube and Primary Carcinoma of the Peritoneum,” <i>J Clin Oncol</i>, 2001, 19(7):1901-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/11283121/pubmed" id="11283121" target="_blank">11283121</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15930421">
<a name="15930421"></a>Martin M, Pienkowski T, Mackey J, et al; Breast Cancer International Research Group 001 Investigators. Adjuvant docetaxel for node-positive breast cancer. <i>N Engl J Med</i>. 2005;352(22):2302-2313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/15930421/pubmed" id="15930421" target="_blank">15930421</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15911866">
<a name="15911866"></a>Marty M, Cognetti F, Maraninchi D, et al, "Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Administered as First-Line Treatment: The M77001 Study Group," <i>J Clin Oncol</i>, 2005, 23(19):4265-74.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/15911866/pubmed" id="15911866" target="_blank">15911866</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33626987">
<a name="33626987"></a>Masood W, Shammas S, Saleem Z, et al. Comparative study of oral and IV dexamethasone premedication in the prevention of docetaxel induced allergic reactions. <i>J Oncol Pharm Pract</i>. 2022;28(1):96-100. doi:10.1177/1078155220984369<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/33626987/pubmed" id="33626987" target="_blank">33626987</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26324367">
<a name="26324367"></a>Masters GA, Temin S, Azzoli CG. Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline update [published correction appears in <i>J Clin Oncol</i>. 2016;34(11):1287]. <i>J Clin Oncol</i>. 2015;33(30):3488-3515<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/26324367/pubmed" id="26324367" target="_blank">26324367</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19906761">
<a name="19906761"></a>Mavroudis D, Papakotoulas P, Ardavanis A, et al, “Randomized Phase III Trial Comparing Docetaxel Plus Epirubicin Versus Docetaxel Plus Capecitabine as First-Line Treatment in Women With Advanced Breast Cancer,” <i>Ann Oncol</i>, 2010, 21(1):48-54.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/19906761/pubmed" id="19906761" target="_blank">19906761</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9164195">
<a name="9164195"></a>McCaffrey JA, Hilton S, Mazumdar M, et al, “Phase II Trial of Docetaxel in Patients With Advanced or Metastatic Transitional-Cell Carcinoma,” <i>J Clin Oncol</i>, 1997, 15(5):1853-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/9164195/pubmed" id="9164195" target="_blank">9164195</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16809732">
<a name="16809732"></a>McKiernan JM, Masson P, Murphy AM, et al. Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy. <i>J Clin Oncol</i>. 2006;24(19):3075-3080. doi:10.1200/JCO.2005.03.1161<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/16809732/pubmed" id="16809732" target="_blank">16809732</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16636537">
<a name="16636537"></a>Mencoboni M, Olivieri R, Vannozzi MO, Schettini G, Viazzi F, Ghio R. Docetaxel pharmacokinetics with pre- and post-dialysis administration in a hemodyalized patient. <i>Chemotherapy</i>. 2006;52(3):147-150. doi:10.1159/000092903<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/16636537/pubmed" id="16636537" target="_blank">16636537</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29152553">
<a name="29152553"></a>Milbar N, Kates M, Chappidi MR, et al. Oncological outcomes of sequential intravesical gemcitabine and docetaxel in patients with non-muscle invasive bladder cancer. <i>Bladder Cancer.</i> 2017;3(4):293-303. doi:10.3233/BLC-170126<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/29152553/pubmed" id="29152553" target="_blank">29152553</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19727011">
<a name="19727011"></a>Mora J, Cruz CO, Parareda A, et al, "Treatment of Relapsed/Refractory Pediatric Sarcomas With Gemcitabine and Docetaxel," <i>J Pediatr Hematol Oncol</i>, 2009, 31(10):723-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/19727011/pubmed" id="19727011" target="_blank">19727011</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21276754">
<a name="21276754"></a>Morgan C, Tillett T, Braybrooke J, et al, “Management of Uncommon Chemotherapy-Induced Emergencies,” <i>Lancet Oncol</i>, 2011, 12(8):806-14.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/21276754/pubmed" id="21276754" target="_blank">21276754</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19786850">
<a name="19786850"></a>Mukai H, Katsumata N, Ando M, et al, “Safety and Efficacy of a Combination of Docetaxel and Cisplatin in Patients With Unknown Primary Cancer,” <i>Am J Clin Oncol</i>, 2010, 33(1):32-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/19786850/pubmed" id="19786850" target="_blank">19786850</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15151954">
<a name="15151954"></a>Muro K, Hamaguchi T, Ohtsu A, et al, “A Phase II Study of Single-Agent Docetaxel in Patients With Metastatic Esophageal Cancer,” <i>Ann Oncol</i>, 2004, 15(6):955-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/15151954/pubmed" id="15151954" target="_blank">15151954</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10334526">
<a name="10334526"></a>Nabholtz JM, Senn HJ, Bezwoda WR, et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. <i>J Clin Oncol.</i> 1999;17(5):1413-1424. doi:10.1200/JCO.1999.17.5.1413<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/10334526/pubmed" id="10334526" target="_blank">10334526</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18484657">
<a name="18484657"></a>Navid F, Willert JR, McCarville MB, et al, “Combination of Gemcitabine and Docetaxel in the Treatment of Children and Young Adults With Refractory Bone Sarcoma,” <i>Cancer</i>, 2008, 113(2):419-25.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/18484657/pubmed" id="18484657" target="_blank">18484657</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12065558">
<a name="12065558"></a>O'Shaughnessy J, Miles D, Vukelja S, et al, “Superior Survival With Capecitabine Plus Docetaxel Combination Therapy in Anthracycline-Pretreated Patients With Advanced Breast Cancer: Phase III Trial Results,” <i> J Clin Oncol</i>, 2002, 20(12):2812-23.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/12065558/pubmed" id="12065558" target="_blank">12065558</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27400984">
<a name="27400984"></a>Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association [published correction appears in <i>Circulation</i>. 2016;134(12):e261]. <i>Circulation</i>. 2016;134(6):e32-e69.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/27400984/pubmed" id="27400984" target="_blank">27400984</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27098543">
<a name="27098543"></a>Palmerini E, Jones RL, Marchesi E, et al. Gemcitabine and docetaxel in relapsed and unresectable high-grade osteosarcoma and spindle cell sarcoma of bone. <i>BMC Cancer.</i> 2016;16:280. doi:10.1186/s12885-016-2312-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/27098543/pubmed" id="27098543" target="_blank">27098543</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23165781">
<a name="23165781"></a>Pasini F, de Manzoni G, Zanoni A, et al, “Neoadjuvant Therapy With Weekly Docetaxel and Cisplatin, 5-Fluorouracil Continuous Infusion, and Concurrent Radiotherapy in Patients With Locally Advanced Esophageal Cancer Produced a High Percentage of Long-Lasting Pathological Complete Response: A Phase 2 Study,” <i>Cancer</i>, 2013, 119(5):939-45.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/23165781/pubmed" id="23165781" target="_blank">23165781</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23813932">
<a name="23813932"></a>Peccatori FA, Azim HA Jr, Orecchia R, et al; ESMO Guidelines Working Group. Cancer, pregnancy and fertility: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. <i>Ann Oncol</i>. 2013;24(suppl 6):vi160-vi170. doi: 10.1093/annonc/mdt199.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/23813932/pubmed" id="23813932" target="_blank">23813932</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11886001">
<a name="11886001"></a>Pectasides D, Glotsos J, Bountouroglou N, et al, “Weekly Chemotherapy With Docetaxel, Gemcitabine and Cisplatin in Advanced Transitional Cell Urothelial Cancer: A Phase II Trial,” <i>Ann Oncol</i>, 2002, 13(2):243-50.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/11886001/pubmed" id="11886001" target="_blank">11886001</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22997449">
<a name="22997449"></a>Perez Fidalgo JA, García Fabregat L, Cervantes A, et al, “Management of Chemotherapy Extravasation: ESMO-EONS Clinical Practice Guidelines,” <i>Ann Oncol</i>, 2012, 23(Suppl 7):167-73.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/22997449/pubmed" id="22997449" target="_blank">22997449</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19318632">
<a name="19318632"></a>Pointreau Y, Garaud P, Chapet S, et al, “Randomized Trial of Induction Chemotherapy With Cisplatin and 5-Fluorouracil With or Without Docetaxel for Llarynx Preservation,” <i>J Natl Cancer Inst</i>, 2009, 101(7):498-506.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/19318632/pubmed" id="19318632" target="_blank">19318632</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Polovich M, Whitford JN and Olsen M, <i>Chemotherapy and Biotherapy Guidelines and Recommendations for Practice</i>, 3rd ed, Pittsburgh, PA: Oncology Nursing Society, 2009.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17960013">
<a name="17960013"></a>Posner MR, Hershock DM, Blajman CR, et al; TAX 324 Study Group. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. <i>N Engl J Med</i>. 2007;357(17):1705-1715. doi:10.1056/NEJMoa070956<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/17960013/pubmed" id="17960013" target="_blank">17960013</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15022294">
<a name="15022294"></a>Pouessel D, Culine S, Becht C, et al, “Gemcitabine and Docetaxel as Front-Line Chemotherapy in Patients With Carcinoma of an Unknown Primary Site,” <i>Cancer</i>, 2004, 100(6):1257-61.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/15022294/pubmed" id="15022294" target="_blank">15022294</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15741225">
<a name="15741225"></a>Pujol JL, Breton JL, Gervais R, et al. Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin. <i>Ann Oncol</i>. 2005;16(4):602-610. doi:10.1093/annonc/mdi126<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/15741225/pubmed" id="15741225" target="_blank">15741225</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22302783">
<a name="22302783"></a>Rapkin L, Qayed M, Brill P, et al. Gemcitabine and docetaxel (GEMDOX) for the treatment of relapsed and refractory pediatric sarcomas. <i>Pediatr Blood Cancer</i>. 2012;59(5):854-858.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/22302783/pubmed" id="22302783" target="_blank">22302783</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18300256">
<a name="18300256"></a>Rivera E, Mejia JA, Arun BK, et al, “Phase 3 Study Comparing the Use of Docetaxel on an Every-3-Week versus Weekly Schedule in the Treatment of Metastatic Breast Cancer,” <i>Cancer</i>, 2008, 112(7):1455-61.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/18300256/pubmed" id="18300256" target="_blank">18300256</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22767144">
<a name="22767144"></a>Roy A, Cunningham D, Hawkins R, et al, “Docetaxel Combined With Irinotecan or 5-Fluorouracil in Patients With Advanced Oesophago-Gastric Cancer: A Randomised Phase II Study,” <i>Br J Cancer</i>, 2012, 107(3):435-41.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/22767144/pubmed" id="22767144" target="_blank">22767144</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19465425">
<a name="19465425"></a>Ruhstaller T, Widmer L, Schuller JC, et al, “Multicenter Phase II Trial of Preoperative Induction Chemotherapy Followed by Chemoradiation With Docetaxel and Cisplatin for Locally Advanced Esophageal Carcinoma (SAKK 75/02),” <i>Ann Oncol</i>, 2009, 20(9):1522-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/19465425/pubmed" id="19465425" target="_blank">19465425</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31990618">
<a name="31990618"></a>Saylor PJ, Rumble RB, Tagawa S, et al. Bone health and bone-targeted therapies for prostate cancer: ASCO endorsement of a Cancer Care Ontario guideline. <i>J Clin Oncol</i>. 2020;38(15):1736-1743. doi:10.1200/JCO.19.03148<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/31990618/pubmed" id="31990618" target="_blank">31990618</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23704196">
<a name="23704196"></a>Schneeweiss A, Chia S, Hickish T, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). <i>Ann Oncol</i>. 2013;24(9):2278-2284. doi:10.1093/annonc/mdt182<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/23704196/pubmed" id="23704196" target="_blank">23704196</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15033673">
<a name="15033673"></a>Schrijvers D, Van Herpen C, Kerger J, et al, “Docetaxel, Cisplatin and 5-Fluorouracil in Patients With Locally Advanced Unresectable Head and Neck Cancer: A Phase I-II Feasibility Study,” <i>Ann Oncol</i>, 2004, 15(4):638-45.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/15033673/pubmed" id="15033673" target="_blank">15033673</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28882536">
<a name="28882536"></a>Seddon B, Strauss SJ, Whelan J, et al. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial. <i>Lancet Oncol</i>. 2017;18(10):1397-1410. doi:10.1016/S1470-2045(17)30622-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/28882536/pubmed" id="28882536" target="_blank">28882536</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26438119">
<a name="26438119"></a>Shah MA, Janjigian YY, Stoller R, et al. Randomized multicenter phase II study of modified docetaxel, cisplatin, and fluorouracil (DCF) versus DCF plus growth factor support in patients with metastatic gastric adenocarcinoma: a study of the US Gastric Cancer Consortium. <i>J Clin Oncol</i>. 2015;33(33):3874-3879. doi:10.1200/JCO.2015.60.7465<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/26438119/pubmed" id="26438119" target="_blank">26438119</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32568633">
<a name="32568633"></a>Shah MA, Kennedy EB, Catenacci DV, et al. Treatment of locally advanced esophageal carcinoma: ASCO guideline. <i>J Clin Oncol.</i> 2020;38(23):2677-2694. doi:10.1200/JCO.20.00866<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/32568633/pubmed" id="32568633" target="_blank">32568633</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27301700">
<a name="27301700"></a>Sharma P, López-Tarruella S, García-Saenz JA, et al. Efficacy of neoadjuvant carboplatin plus docetaxel in triple-negative breast cancer: combined analysis of two cohorts. <i>Clin Cancer Res.</i> 2017;23(3):649-657. doi:10.1158/1078-0432.CCR-16-0162<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/27301700/pubmed" id="27301700" target="_blank">27301700</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30061361">
<a name="30061361"></a>Sharma P, López-Tarruella S, García-Saenz JA, et al. Pathological response and survival in triple-negative breast cancer following neoadjuvant carboplatin plus docetaxel. <i>Clin Cancer Res.</i> 2018;24(23):5820-5829. doi:10.1158/1078-0432.CCR-18-0585<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/30061361/pubmed" id="30061361" target="_blank">30061361</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10811675">
<a name="10811675"></a>Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. <i>J Clin Oncol.</i> 2000;18(10):2095-2103. doi:10.1200/JCO.2000.18.10.2095<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/10811675/pubmed" id="10811675" target="_blank">10811675</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22932694">
<a name="22932694"></a>Shim HJ, Kim DE, Hwang JE, et al, “A Phase II Study of Concurrent Chemoradiotherapy With Weekly Docetaxel and Cisplatin in Advanced Oesophageal Cancer,” <i>Cancer Chemother Pharmacol</i>, 2012, 70(5):683-90.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/22932694/pubmed" id="22932694" target="_blank">22932694</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21991949">
<a name="21991949"></a>Slamon D, Eiermann W, Robert N, et al, “Adjuvant Trastuzumab in HER2-Positive Breast Cancer,” <i>N Engl J Med</i>, 2011, 365(14):1273-83.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/21991949/pubmed" id="21991949" target="_blank">21991949</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23130564">
<a name="23130564"></a>Smallridge RC, Ain KB, Asa SL, et al; American Thyroid Association Anaplastic Thyroid Cancer Guidelines Taskforce. American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. <i>Thyroid</i>. 2012;22(11):1104-1139. doi:10.1089/thy.2012.0302<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/23130564/pubmed" id="23130564" target="_blank">23130564</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35179323">
<a name="35179323"></a>Smith MR, Hussain M, Saad F, et al; ARASENS Trial Investigators. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. <i>N Engl J Med.</i> 2022;386(12):1132-1142. doi:10.1056/NEJMoa2119115<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/35179323/pubmed" id="35179323" target="_blank">35179323</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7654428">
<a name="7654428"></a>Smyth JF, Smith IE, Sessa C, et al, “Activity of Docetaxel (Taxotere) in Small Cell Lung Cancer. The Early Clinical Trials Group of the EORTC,” <i>Eur J Cancer</i>, 1994, 30A(8):1058-60.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/7654428/pubmed" id="7654428" target="_blank">7654428</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31821066">
<a name="31821066"></a>Steinberg RL, Thomas LJ, Brooks N, et al. Multi-institution evaluation of sequential gemcitabine and docetaxel as rescue therapy for nonmuscle invasive bladder cancer. <i>J Urol.</i> 2020;203(5):902-909. doi:10.1097/JU.0000000000000688<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/31821066/pubmed" id="31821066" target="_blank">31821066</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30561441">
<a name="30561441"></a>Steinberg RL, Thomas LJ, O'Donnell MA, Nepple KG. Sequential intravesical gemcitabine and docetaxel for the salvage treatment of non-muscle invasive bladder cancer. <i>Bladder Cancer</i>. 2015;1(1):65-72. doi:10.3233/BLC-150008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/30561441/pubmed" id="30561441" target="_blank">30561441</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27686945">
<a name="27686945"></a>Sun Y, Li WF, Chen NY, et al. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. <i>Lancet Oncol.</i> 2016;17(11):1509-1520. doi:10.1016/S1470-2045(16)30410-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/27686945/pubmed" id="27686945" target="_blank">27686945</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23602601">
<a name="23602601"></a>Swain SM, Kim SB, Cortés J, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. <i>Lancet Oncol</i>. 2013;14(6):461-471.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/23602601/pubmed" id="23602601" target="_blank">23602601</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26244877">
<a name="26244877"></a>Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. <i>N Engl J Med</i>. 2015;373(8):737-46.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/26244877/pubmed" id="26244877" target="_blank">26244877</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21723596">
<a name="21723596"></a>Symonds RP, Davidson SE, Chan S, et al. SCOTCERV: a phase II trial of docetaxel and gemcitabine as second line chemotherapy in cervical cancer. <i>Gynecol Oncol</i>. 2011;123(1):105-109. doi: 10.1016/j.ygyno.2011.06.001.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/21723596/pubmed" id="21723596" target="_blank">21723596</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15470213">
<a name="15470213"></a>Tannock IF, de Wit R, Berry WR, et al; TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. <i>N Engl J Med.</i> 2004;351(15):1502-1512. doi:10.1056/NEJMoa040720<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/15470213/pubmed" id="15470213" target="_blank">15470213</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Taxotere (docetaxel) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis; January 2023.</div>
</li>
<li>
<div class="reference">
                  Taxotere (docetaxel) [product monograph]. Laval, Quebec, Canada: Sanofi-aventis Canada Inc; June 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10427584">
<a name="10427584"></a>Thiesen J and Kramer I, “Physico-Chemical Stability of Docetaxel Premix Solution and Docetaxel Infusion Solutions in PVC Bags and Polyolefine Containers,” <i>Pharm World Sci</i>, 1999, 21(3):137-41.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/10427584/pubmed" id="10427584" target="_blank">10427584</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17075117">
<a name="17075117"></a>Van Cutsem E, Moiseyenko VM, Tjulandin S, et al, “Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil as First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study Group,” <i>J Clin Oncol</i>, 2006, 24(31):4991-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/17075117/pubmed" id="17075117" target="_blank">17075117</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24713311">
<a name="24713311"></a>van Hasselt JG, van Calsteren K, Heyns L, et al. Optimizing anticancer drug treatment in pregnant cancer patients: pharmacokinetic analysis of gestation-induced changes for doxorubicin, epirubicin, docetaxel and paclitaxel. <i>Ann Oncol</i>. 2014;25(10):2059-2065.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/24713311/pubmed" id="24713311" target="_blank">24713311</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15547181">
<a name="15547181"></a>Vasey PA, Jayson GC, Gordon A, et al, “Phase III Randomized Trial of Docetaxel-Carboplatin Versus Paclitaxel-Carboplatin as First-line Chemotherapy for Ovarian Carcinoma,” <i>J Natl Cancer Inst</i>, 2004, 96(22):1682-91.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/15547181/pubmed" id="15547181" target="_blank">15547181</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17960012">
<a name="17960012"></a>Vermorken JB, Remenar E, van Herpen C, et al; EORTC 24971/TAX 323 Study Group. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. <i>N Engl J Med</i>. 2007;357(17):1695-1704. doi:10.1056/NEJMoa071028<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/17960012/pubmed" id="17960012" target="_blank">17960012</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26582454">
<a name="26582454"></a>Yang L, Zhang XC, Yu SF, et al. Pharmacokinetics and safety of cyclophosphamide and docetaxel in a hemodialysis patient with early stage breast cancer: a case report. <i>BMC Cancer</i>. 2015;15:917. doi:10.1186/s12885-015-1932-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/26582454/pubmed" id="26582454" target="_blank">26582454</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16532433">
<a name="16532433"></a>Zwerdling T, Krailo M, Monteleone P, et al; Children's Oncology Group. Phase II investigation of docetaxel in pediatric patients with recurrent solid tumors: a report from the Children's Oncology Group. Cancer. 2006;106(8):1821-1828.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/docetaxel-drug-information/abstract-text/16532433/pubmed" id="16532433" target="_blank">16532433</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9381 Version 594.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
